IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Wieder

SERIAL NO. : 10/521,841 EXAMINER: Meera Natarajan, PhD

FILED: July 27, 2005 ART UNIT: 1643

FOR : ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATHWAY

DECLARATION OF ROBERT WIEDER

I, Robert Wieder, hereby declare that:

1. I am a citizen of the United States and reside at 1380 Outlook Drive West, Mountainside, NJ 07092.

2. I received a BA degree in Biochemistry and Biology from the University of Pennsylvania in 1976, a Master of Philosophy (M. Phil.) and a Ph.D. in Biomedical Sciences from the Mount Sinai School of Medicine of the City University of New York in 1982 and an M.D. degree from the Mount Sinai School of Medicine in 1983. I trained in Internal Medicine at the Montefiore Medical Center of the Albert Einstein School of Medicine from 1983 to 1985, as a Medical Staff Fellow at the National Heart, Lung and Blood Institute of the National Institutes of Health from 1985 to 1988, and as a fellow in Medical Oncology/Hematology at Memorial Sloan Kettering Cancer Center from 1988 to 1992. I was employed as an attending physician on the Autologous Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center from 1992 to 1993. I have been employed at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School as a faculty member from 1993 to the present time. The details of my education and professional history are set forth in my curriculum vitae, attached hereto as Exhibit A.

3. I have over 33 years experience in the fields of biomedical sciences and medicine.

4. I am the author or co-author of more than 36 scientific articles on the subjects of biology, biophysics and oncology. A list of these articles is set forth in my curriculum vitae, attached hereto. My current area of research involves dormancy and survival signaling in breast cancer micrometastases in the bone marrow and interaction of micrometastatic breast cancer cells with the bone marrow microenvironment.

5. I am an inventor of the subject matter disclosed and claimed in United States Patent Application Number 10/521,841 (hereinafter the '841 application).

Statements Regarding the Defects of Varner and Li et al.

6. I have read and discussed with counsel the Official Action dated April 24, 2009, received in connection with the '841 application. I understand the nature of the rejections made by the Examiner concerning Varner [United States Patent Number (USPN) 7,311,911] in view of Li et al. (United States Publication Serial Number 2004/0048312).

7. The Office Action acknowledges that Varner does not teach or suggest adjuvant therapy. As an expert in the field, I can confirm that there is no teaching in Varner that relates to an adjuvant setting. Indeed, as taught throughout Varner, the intended therapeutic purpose with regard to patients with cancer is to reduce or inhibit tumor angiogenesis. It is well understood in the field of clinical oncology that a therapeutic purpose directed to reducing or inhibiting tumor angiogenesis only pertains to a patient with detectable disease (i.e., a detectable tumor or tumors). In contrast, my invention relates to a method for treating a patient in an adjuvant setting, wherein the patient fails to exhibit signs of detectable disease. It is, therefore, apparent that the method of the present invention and that of Varner are directed to distinct patient populations.

8. In light of the above, the statements in the Office Action pertaining to Varner

allegedly teaching that administration to a subject can either be over a relatively short period of time or can be over a more prolonged period of time and that different therapeutic protocols can be used to achieve the most effective regimen are misapplied. In keeping with the teachings of Varner, such guidance only relates to a method for reducing or inhibiting angiogenesis for therapeutic purposes. Wherein the therapeutic purpose relates to the treatment of cancer in a patient, the intended purpose is to reduce or inhibit tumor angiogenesis. Thus, the teaching of Varner pertaining to treatment duration and therapeutic protocol would be understood by an ordinarily skilled practitioner to apply to treatment of a patient with detectable disease.

9. The Office Action looks to Li et al. for purportedly teaching adjuvant therapy. The Office Action concludes that the combined teachings of Varner and Li et al. would allegedly lead an ordinarily skilled practitioner to realize my invention. I disagree for a variety of reasons. To begin, the Li et al. patent application is directed in its entirety to integrin αvβ6 and its role in human cancers and a monoclonal antibody (mBLA3) specific for integrin αvβ6. As shown in Figure 1 of Exhibit B (attached), I assessed and did not observe an increase in the expression of either αv or β6 in the dormant (growth arrested) breast cancer cells analyzed as taught in the present specification. For the record, Figure 1 of Exhibit B is identical to that of Figure 5A or 5B of the instant specification (United States Publication Number 2006/0035825), except that the arrows have been altered to be directed to the positions corresponding to αv and β6 mRNA on the microarray. Furthermore, Figure 13A of the instant specfication demonstrates clearly and unambiguously that adhesion of dormant growth arrested breast cancer cells to fibronectin, a ligand for both integrins α5β1 and αvβ6, depends on integrin α5 but is unaffected by blocking antibody to integrin αv. This complements the gene array expression data demonstrating a lack of expression of integrin αvβ6 in dormant breast cancer cells with a functional assay demonstrating a dependence of survival on integrin α5, which is contrasted with a complete lack of dependence on integrin αv. These results demonstrate unequivocally that αv and β6 do not play a significant role in the survival of dormant (growth arrested) breast cancer cells in the bone marrow microenvironment.

10. Moreover, in view of the teaching in the instant specification regarding the identity of the microarray used for the analysis presented in Figures 5A and 5B (see, for example, paragraph [0031]), an ordinarily skilled practitioner would have been able to identify which spots on the grid correspond to αv and β6 mRNA on the microarray should such a practitioner have been motivated to investigate the expression of these mRNAs in the context of dormant breast cancer cell micrometastases. Indeed, I perform similar evaluations on microarray analyses published in the literature as a matter of routine practice. In short, all that an ordinarily skilled practitioner requires in this regard is the supplier and product name/catalog number of the microarray, because the identity of the particular positions/spots on the array is publicly available. Thus, in the unlikely event that an ordinarily skilled practitioner might have thought to combine the teachings of Varner and Li et al., the microarray data (Figures 5A and 5B) and the functional data (Figure 13A) presented in the instant specification would have discouraged such a practitioner from pursuing the combination. My results suggest that such a combination of teachings would not have had a reasonable expectation for success because αvβ6 integrin is not expressed in dormant breast cancer cell micrometastases

11. The results presented in Figure 1 and general knowledge in the field also underscore the fact that integrins represent a very diverse family of proteins. Integrins exhibit dissimilar functions and such functions are, in turn, modified differentially in the context of different cellular environments. Thus, an ordinarily skilled practitioner would appreciate that what is determined to be true for one integrin cannot accurately be extrapolated to apply to any other integrin. That being said, there is no scientific basis for imagining that teaching the use of antibodies to a particular integrin in an adjuvant setting extends to the use of antibodies to any other integrin in any adjuvant setting. An ordinarily skilled practitioner would appreciate that in the absence of evidence indicating which integrin or integrins are relevant in a particular clinical setting with respect to expression and activity, there is no way to predict whether antibodies to a particular integrin will have any clinical utility. Furthermore, my data demonstrate that antibodies to αvβ6 integrin are unlikely to have any clinical utility in the context of breast cancer

cell micrometastases in the bone marrow because αvβ6 integrin is not expressed on these cells. See Exhibit B.

12. Moreover, the literature appears to show a consensus that αvβ6 increases with carcinogenesis in most primary tumors and some metastases, but primarily in squamous cell carcinomas, as well as in colon and ovarian epithelial cells. Expression appears to increase with cell crowding. There are no data on expression in breast cancer metastases. In the paper by Van Aarsen et al. (submitted previously), only a minority of primary breast carcinomas express this fibronectin binding integrin. Accordingly, since there are no data on metastasis, no significant role attributed to primary breast tumors, no evidence of expression in metastatic breast cancer cells and no evidence of an increase in dormant cells, there appears to be no prior data supporting a role for integrin αvβ6 in survival of dormant micrometastatic breast cancer cells in the bone marrow. The literature, therefore, fails to provide support for a role for integrin αvβ6 as a target for adjuvant therapy.

13. In summary, Varner teaches therapeutic regimens that inhibit angiogenesis and call for inhibition of α5β1 integrin signaling, but Varner fails to teach adjuvant therapy. The Li et al. application mentions adjuvant therapy in passing, but is focused in its entirety on αvβ6 integrin and its role in human cancers and a monoclonal antibody (mBLA3) specific for αvβ6 integrin. An ordinarily skilled practitioner would appreciate that α5β1 integrin and αvβ6 integrin are functionally disparate integrins and would not, therefore, consider it obvious to apply teachings pertaining to one integrin to that of the other. The literature, moreover, fails to teach or suggest any role for αvβ6 integrin in growth arrested cancer cells in general or growth arrested breast cancer cells in particular, nor any evident role in metastatic or micrometastatic breast cancer. In contrast, the literature affirms a role for αvβ6 integrin in rapidly proliferating cancer cells (i.e., non-dormant cancer cells). My data demonstrate that αvβ6 integrin is not expressed in dormant (growth arrested) breast cancer cells in the bone marrow microenvironment. See Figures 5A, 5B, and 13A of the application as filed and Figure 1 of Exhibit B. Taken together, these facts

would dissuade an ordinarily skilled artisan from combining the teachings of Varner and Li et al. Indeed, the facts in combination teach away from the presently claimed invention.

14. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful statements may jeopardize the validity of the above-referenced application or any patent issued thereon.

9/15/09
DATE

NAME ROBERT WIEDER, MD, PhD

EXHIBIT A

DATE 9/15/09

CURRICULUM VITAE

NAME: Robert Wieder

HOME ADDRESS: 1380 Outlook Drive West
Mountainside, New Jersey 07092
Telephone: 908-377-1465

OFFICE ADDRESS:
UMDNJ-New Jersey Medical School
Cancer Center H1216
185 South Orange Avenue
Newark, NJ 07103
Telephone:(973) 972-4871
E-mail: wiederro@umdnj.edu

1. EDUCATION:

a. Undergraduate:

University of Pennsylvania, Philadelphia, PA
1976 B.A. in Biochemistry and Biology

b. Graduate and Professional:

Mount Sinai School of Medicine of the City University of NY, New York, NY
1982 M.Phil. in Biomedical Sciences
1982 Ph.D. in Biomedical Sciences
1983 M.D.

2. POSTDOCTORAL TRAINING

a. Internship and Residencies:

1983-1985 Intern and Junior Resident, Internal Medicine, Montefiore Hospital Medical Center, Albert Einstein College of Medicine, Bronx, NY
1985-1986 Medical Staff Fellow, Clinical Associate, National Heart, Lung and Blood Institute, NIH, Bethesda, MD
1988-1992 Fellow, Medical Oncology/Hematology, Memorial Sloan-Kettering Cancer Center, New York, NY

b. Research Fellowships:

1986-1988 Medical Staff Fellow, Laboratory of Molecular Hematology, National Heart, Lung and Blood Institute, NIH, Bethesda, MD

3. MILITARY
None

4. LICENSURE
   a. N.J. Medical License: MA 60226, 1993
   b. Other State Medical License: N.Y., 159293, 1984

5. CERTIFICATION
   Board Certified: Internal Medicine, #107202
   Medical Oncology, #107202

6. NARCOTICS CERTIFICATION
   U.S. BW 3903261
   N.J. DO 63847

7. UNIVERSITY APPOINTMENTS
   1992-1993 Instructor, Cornell University Medical College, New York, NY
   1992-1993 Instructor, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
   1993-2000 Assistant Professor, Department of Medicine, UMDNJ-New Jersey Medical School
   1997-present Assistant Professor, Department of Microbiology and Molecular Genetics, UMDNJ-New Jersey Medical School
   1997-present Assistant Professor, Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences
   1996-1999 Interim Director, Division of Oncology, Department of Medicine, UMDNJ-New Jersey Medical School
   1999-2001 Interim Director, Division of Oncology/Hematology, Department of Medicine, UMDNJ-New Jersey Medical School
   1998-2001 Associate Director, Clinical Research, UMDNJ-Cancer Center/ Newark
   1997-present Research Associate Member, Cancer Institute of New Jersey
   2000-present Associate Professor, Dept. of Medicine, UMDNJ-NJ Medical School
   2005-present Director, Clinical Research Office, UMDNJ-NJ Medical School/University Hospital Cancer Center
   2009-present Co-Medical Director, Center for Clinical and Translational Science, UMDNJ-NJ Medical School

8. HOSPITAL APPOINTMENTS
   1983-1985 Montefiore Hospital, Medical Center, Bronx, NY, Housestaff
   1983-1985 North Central Bronx Hospital, Bronx, NY, Housestaff
   1985-1988 NIH Clinical Center, Medical Staff Fellow
   1988-1992 Memorial Sloan-Kettering Cancer Center, New York, NY, Fellow, Medical Oncology/Hematology
   1988-1992 Cornell Medical Center, New York, NY, Fellow, Medical Oncology/Hematology
   1992-1993 Memorial Sloan-Kettering Cancer Center, Attending Physician Leukemia Service, Autologous Bone Marrow Transplant Unit
   1994-present UMDNJ-University Hospital, Medical Oncology/Hematology

9. OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS

July-Sept., 1987 Special Fellow, Adult Bone Marrow Unit, Memorial Sloan-Kettering Cancer Center, New York, NY

10. AWARDS AND HONORS

1976	B.A. Cum Laude and Honors in Biochemistry
1980	NIH Medical Student Research Fellow
1981-1982	Mount Sinai Medical Scientist Fellow
1988-1989	American Cancer Society Clinical Oncology Fellow
1990-1991	Mortimer J. Lacher Fellow
1990-1992	Memorial Sloan-Kettering Cancer Center Clinical Scholars Biomedical Research Fellow
1990-1992	Charles A. Dana Fellow
1992	ASCO Travel Award
1994	Foundation of the University of Medicine and Dentistry of New Jersey Grant Award
1994	US Army Breast Cancer Research Prog. Career Development Award
1998	State of New Jersey Commission on Cancer Research Outstanding Breast Cancer Researcher Award
2001	State of New Jersey Commission on Cancer Research Service Recognition Award
2001	UMDNJ-New Jersey Medical School Faculty Association Clinical Sciences Faculty of the Year

11. BOARDS OF DIRECTORS/TRUSTEES none

12. MAJOR COMMITTEE POSITIONS AND MAJOR VISITING APPOINTMENTS

Extrainstitutional

1995-1996	Member, Special Awards Committee, American Soc. Clinical Oncology
1995-pres.	NJ State Comm. on Cancer Research Breast Cancer Advisory Board, Chair 1998-2001, 2006-present
1996-2005	Program Review Committee, Annual New Jersey Breast Cancer Research Symposium
1997	Program Review Committee, Annual Scientific Retreat of the Cancer Institute of New Jersey and The New Jersey State Commission on Cancer Research
1997-2004	Cancer Institute of New Jersey Protocol Advisory Committee
1999	Research Planning Committee, Annual Scientific Retreat of the Cancer Institute of New Jersey and The New Jersey State Commission on Cancer Research
1999-2000	Member, State of New Jersey Department of Health and Senior Services Circle of Friends Advisory Board
2002-present	Extrainstitutional Member, Mount Sinai School of Medicine Institutional Biosafety Committee
2003	Program Review Committee, Annual Scientific Retreat of the Cancer

Institute of New Jersey and The New Jersey State Commission on Cancer Research

2009-present Cancer Institute of New Jersey Clinical Trial Network Steering Committee

Institutional

NIH

1886-1988 NIH Bioethics Liaison Group

1987 Consultant, Working Group on General Information, Human Gene Therapy Subcommittee, NIH Recombinant DNA Advisory Committee.

UMDNJ

1993-1997 Medical School Admissions Committee

1994-present M.D./Ph.D Committee, UMDNJ-NJMS/Graduate School Biomedical Sciences, Member Program Committee and Advisory Council, Associate Director (Clinical) - 1998-2003

1994-1995 Dean's Search Committee for Chair of Biochemistry and Molecular Biology, New Jersey Medical School

1994-1995 Search Committee for Director of Oncology/Hematology, UMDNJ-NJ Medical School

1993-1997 NJMS Research Office Summer Student Research Program Advisory Comm.

1993-1996 NJMS Dept. of Medicine Committee on Medicare Patient Outcomes Research

1995-present NJMS Faculty Investigator Group

1995 Search Committee for Director of Oncology, Beth Israel Medical Center, Newark, NJ,

1995-1997 Dean's Biomedical Research Support Committee

1995-2001 Founding Member Internal Medicine Resident Research Committee

1995-1996 Dean's Self-Study Task Force, Med. School Clin. Science Depts. Commitee

1995-2000 Screening Access of Value to Elderly Women Coalition (SAVE), Women's Wellness Center, UMDNJ-New Jersey Medical School

1996-2003 UMDNJ/University Hospital Oncology Committee

1996 Dean's Committee on the Oncology Program

1996-2000 Dean's Research Advisory Group

1996-2000 IAMS Research Planning Committee

1996-2000 UMDNJ Committee on Bloodless Surgery and Medicine

1997-1998 Internal Medicine Residency Curriculum Committee

1997-1998 Dean's Committee on Research Space Allocation at NJ Medical School

1997-1998 Steering Committee, the Cancer Center at New Jersey Medical School

1998 Dean's Space Advisory Committee

1998-2000 NJMS Research Planning and Priorities Committee

1998-1999 Cancer Center Executive Committee

1999-2001 NJMS cancer education program committee

1999-2001 UMDNJ-UH Pain Management Committee

1999-2000 UMDNJ-UH Cancer Program Survey Team 2000

2000-2001 Cancer Center Steering Committee

2001 Ad hoc Searle, Pew and Sinsheimer Scholars review committees
2001 UMDNJ-NJMS Dept. Medicine Retreat Research Planning Committee
2001-2003 UMDNJ-NJMS Department of Medicine Research Committee
2001-2004 Dean's Search Committee for Chair of Pediatrics, NJ Medical School
2002-2006 UMDNJ-NJMS Cancer Center Animal Facility Advisory Committee
2003-2007 UMDNJ-NJMS Basic Science/Translational Task Force
2003-present UMDNJ-Newark Campus Institutional Review Board
2004-2005 UMDNJ Research Conflicts of Interest Committee
2004 NJMS/UH Cancer Center Director Search Committee
2004-present NJMS Cancer Education Program Executive Committee
2004-present NJMS Biomedical Research Support Committee
2004-present NJMS-UH Cancer Center Committee for Basic and Translational Research
2004-2005 UMDNJ-NJMS Search Committee for Faculty of Biostatistics
2005 UMDNJ-NJMS/UH Cancer Center Search Committee for Chief Operating Officer
2005-present NJMS-UH Cancer Center Faculty Search Committee
2007 Coordinator of NJMS-UH Cancer Center Science Grand Rounds
2007-2008 UMDNJ-NJMS Faculty Committee on Appointments and Promotions
2009-present Member, Clinical Research Leadership Group, UMDNJ-NJMS Center for Clinical and Translational Science

13. MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES

1992 Member, The American Society of Hematology
1994 Member, American Society of Clinical Oncology; Special Awards Committee (95-96)
1994 Member, American Association for Cancer Research
1995 Member, American Society for Blood and Marrow Transplantation
1997 Member, The Harvey Society
2002 Member, European Society of Medical Oncology
2005 Member, Metastasis Research Society

14. MAJOR RESEARCH INTERESTS

a. Dormancy and survival signaling in breast cancer
b. Roles of retinoids and vitamin D analogues in breast cancer
c. Gene therapy for treatment of cancer
d. Clinical trials in Oncology in minority patients

15. GRANT HISTORY

Past support

a. Principal investigator

Title: Clinical Oncology Fellowship #88-144.
Agency: American Cancer Society
Direct Costs: $10,000.
Period: 7/1/88-6/30/89

Title: Training Grant #T32 CA-09512-07
Agency: NIH
Direct Costs: $30,000.
Period: 7/1/89-6/30/90
Title: Biomedical Scholar Award
Agency: Memorial Sloan-Kettering Cancer Center
Direct Costs: $60,000.
Period: 7/1/90-6/30/92

Title: Leukemia Research, unrestricted
Agency: United Food and Commercial Workers Union Leukemia Fund.
Direct Costs: $ 5,000.
Period: 1995

Title: Apoptosis in breast cancer, unrestricted
Agency: Friends of Charity
Direct Costs: $ 15,500.
Period: 1995

Title: Breast Cancer Research Symposium of New Jersey
Agency; New Jersey Commission on Cancer Research
Direct Costs: $10,000.
Period: 1996

Title: Research grant: The Role of basic fibroblast growth factor in human breast cancer.
Agency: Foundation of the University of Medicine and Dentistry of New Jersey.
Direct Costs: $ 48,900.
Period: 7/1/94-6/30/95 (extended without additional funds to 6/30/97)

Title: Career Development Award AIBS #200, DAMD17-94-J-4463:
The Role of basic fibroblast growth factor in human breast cancer.
Agency: DOD, U.S. Army Breast Cancer Research Program.
Direct Costs: $ 200,000.
Period: 10/1/94-9/30/98

Title: Phase II study of the efficacy of Doxil (Doxorubicin HCl liposome injection, Sequus Pharmaceuticals Inc., Menlo Park, CA 94025) in stage IV breast cancer.
Agency: Sequus Pharmaceuticals, Inc., Menlo Park, CA
Direct Costs: $ 14,100.
Period: 1997-1999

Title: Phase I/II trial of 13-cis-retinoic acid (Accutane), Paclitaxel (Taxol) and Carboplatin in recurrent of metastatic squamous cell carcinoma of the head and neck.
Agency: Bristol-Myers, Inc.
Direct Costs: $ 46,059.
Period: 1997-1999

Title: Differentiation of Breast Cancer by Retinoids and Vitamin D_3
Agency: State of New Jersey Commission on Cancer Research
Direct Costs: $ 45,455.
Period: 1998-2000
Title: A Phase I Study of Oral ILX 23-7553 Administered Daily × 5 Every 2 Weeks in Patients With Solid Tumors
Agency: Ilex Oncology
Direct Costs: $ 52,800.
Period: 1999-2002

Title: Roles of all-*trans* retinoic acid and vitamin D_3 in potentiating cell death signaling by Taxotere in breast and prostate cancer
Agency: Aventis, Inc.
Direct Costs: $ 133,500.
Period: 2000-2002

Title: Potentiation of Taxotere-induced cytotoxicity by flavopiridol in breast cancer cells
Agency: Aventis, Inc.
Direct Costs: $ 98,464.
Period: 2002-2003

Title: Research grant: DAMD17-01-C-0343:
The Roles of FGF-2, TGF Beta, and TGF Beta Receptor 2 in Breast Cancer Dormancy.
Agency: DOD, U.S. Army Breast Cancer Research Program.
Direct Costs: $ 230,509.
Period: 7/1/01-6/30/03

Title: The Role of Bone Marrow Stromal FGF-2 in Breast Cancer Dormancy.
Agency: State of New Jersey Commission on Cancer Research 02-1140-CCR-E0
Direct Costs: $ 136,364. (Collaboration with Rider U.) Direct to our lab: $68,182.
Period: 6/1/02-5/30/04

Title: Phase II Trial of 13-*cis* retinoic acid (Accutane), paclitaxel (Taxol) and paraplatin (Carboplatin) in invasive, recurrent or metastatic squamous cell carcinoma of the cervix
Agency: Bristol-Myers, Inc.
Direct Costs: $ 122,946.
Period: 2001-2004

Title: Research grant: DAMD17-03-1-0524:
Overcoming Bone Marrow Stroma-Mediated Chemoresistance in Metastatic Breast Cancer Cells.
Agency: DOD, U.S. Army Breast Cancer Research Program.
Direct Costs: $ 312,903.
Period: 7/1/03-6/30/06

Title: Phase II trial of Vesanoid (TRETINOIN, all-*trans* retinoic acid) and Taxol (Paclitaxel) in

patients with stage IV breast cancer
Agency: Bristol-Myers, Inc.
Direct Costs: $ 70,000.
Period: 1999-2006

Title: Mechanisms involved in the treatment and prevention of breast cancer by 1,25-dihydroxyvitaminD_3
Co-equal PI: with Sylvia Christakos, Department of Biochemistry and Molecular Biology, UMDNJ-NJMS
Agency: NJMS-UH Cancer Center Research Grants Program
Direct Costs: $80,000.
Period: 2006-2007

Title: Signal pathway activation signature of cisplatin resistance in head and neck cancer
Role: Co-equal PI (with Erik Cohen) 20% effort
Agency: Foundation of UMDNJ
Direct Costs: $ 70,000.
Period: 2007-2008

Title: Effects of perscription coverage on control of cancer pain: 08-1096-CCR-EO
Role: PI 10% effort
Agency: New Jersey Commission on Cancer Research
Direct Costs: $ 18,000.
Period: 2007-2008

Title: Elimination of dormant breast cancer cells by targeting survival signaling
Role: PI 10% effort
Agency: Ruth Estrin Goldberg Foundation
Direct Costs: $ 25,000.
Period: 2008-2009

b. Co-Investigator:
Title: Summer Fellowship (with Karen J. Finnigan): The roles of basic FGF in breast cancer
Agency: New Jersey Commission on Cancer Research
Direct Costs: $2,800.
Period: 7/1/94-8/31/94

Title: Outstanding Breast Cancer Research Fellowship (with Qin Wang): Modulation of apoptosis by basic FGF in breast cancer
Agency: State of New Jersey Commission on Cancer Research
Direct Costs: $50,000.
Period: 9/5/97-9/4/99

Title: Post-Doctoral Supplement to NJCCR Breast Cancer Research Fellowship (Qin Wang)
Agency: Foundation of UMDNJ
Direct Costs: $10,000.
Period: 9/5/97-9/4/99

Title: Community Cancer Screening for Black/Hispanic Women
Agency: Centers for Disease Control and Prevention
Direct Costs: $5,000.
Period: 9/30/99-9/29/00

Title: Summer Fellowship (with Ilan Seth Weinberg): Eligibility screening for a Phase I colon cancer vaccine protocol
Agency: New Jersey Commission on Cancer Research
Direct Costs: $2,800.
Period: June-August, 2000
Title: Summer Fellowship (with Jeaudine Evadne Bontemps): NSABP P-2 Trial: Study of Tamoxifen and Raloxifene (STAR) for the prevention of breast cancer
Agency: New Jersey Commission on Cancer Research
Direct Costs: $2,800.
Period: June-August, 2000

Title: Summer Fellowship (with Michael Lindy): Overcoming Breast Cancer Dormancy in the Bone Marrow Microenvironmnet
Agency: New Jersey Commission on Cancer Research
Direct Costs: $2,800.
Period: June-August, 2003

Title: Summer Fellowship: Mediation of Survival Signaling in Dormant Breast Cancer Cells through PI3 kinase and Rho
PI: Bryan Benn
Agency: New Jersey Commission on Cancer Research
Direct Costs: $2,800.
Period: June-August, 2004

Title: Inhibition of Breast Cancer Growth by Vitamin D
PI: Sylvia Christakos, Department of Biochemistry and Molecular Biology, UMDNJ-NJMS
Agency: AHEPA Foundation
Dircet Costs: $10,000.
Period: 2004-2005

Title: Summer Fellowship (with Joanna Sesti): Role retinoic acid in disrupting survival signaling in dormant breast cancer cells
Agency: New Jersey Commission on Cancer Research
Direct Costs: $2,800.
Period: June-August, 2006

Title: Potentiation of radiation-induced cytotoxicity in 1483 head and neck squamous cell carcinoma by COX-2 inhibition
Co-PI: Erik G. Cohen, Department of Surgery, UMDNJ-NJMS
Agency: Foundation of UMDNJ
Direct Costs: $50,000.

Period: 2004-2006

Title: Signal pathway activation signature of cisplatin resistance in head and neck cancer
Role: Joint Co-PI with Erik Cohen 20% effort
Agency: Foundation of UMDNJ
Direct Costs: $ 70,000.
Period: 2007-2008

Title: Role of Integrin Signaling in Resistance to Chemotherapy in Head and Neck Squamous Cell Carcinoma
Role: Co- PI (with Erik Cohen) 10% effort
Agency: Ruth Estrin Goldberg Foundation
Direct Costs: $ 25,000.
Period: 2007-2008

Present support

a. Principal investigator
Title: Use and evaluation of an ethnically-matched patient navigator to increase minority patient recruitment to breast cancer clinical trials
Role: PI 10% effort
Agency: The Susan G. Komen Breast Cancer Foundation of Northern New Jersey
Direct Costs: $195,000.
Period: 2007-2010

Title: Cancer Center Patient Navigator Program
Role: PI 20% effort
Agency: C.R. Bard Foundation
Direct Costs: $ 50,000.
Period: 2007-2009

Title: Research grant: W81XWH-09-1-0119
Reactivation of Breast Cancer Micrometastases by Senescent Bone Marrow Stroma (Human)
Agency: DOD, U.S. Army Breast Cancer Research Program.
Role: PI 15% effort
Direct Costs: $ 375,000.
Period: 7/1/09-6/30/12

Title: Reactivation of breast cancer micrometastases by senescent bone marrow stroma
Role: PI 20%
Agency: NJMS Dean's Annual Bridge Grant Program
Direct Costs: $25,000.
Period: 2008-2010

Title: Research grant: 1 R21 CA142537-01A1

Reactivation of Breast Cancer Micrometastases by Senescent Bone Marrow Stroma (Murine)
Agency: NCI
Role: PI 11.6% effort
Direct Costs: $ 242,000.
Period: 7/1/09-6/30/11

Title: Minority Breast Cancer Navigator Program
Role: PI 10%
Agency: Susan G. Komen for the Cure of Northern New Jersey
Direct Costs: 16,000.
Period: 2009-2010

Title: UMDNJ-NJMS/UH Cancer Center Clinical Research Program
Role: PI 15%
Agency: New Jersey Commission on Cancer Research - New Jersey Cancer Research Development Award
Direct Costs: $ 427,595.
Period: 2009-2010

Title: Research grant: 1U10CA128506-01A1
Minority-Based CCOP at UMDNJ-NJ Medical School/University Hospital Cancer Center
Agency: NCI
Role: PI 30% effort
Direct Costs: $ 1,188,911.
Period: 8/24/09-5/31/12

b. Co-investigator

-

Provisional Patent disclosures filed

2002 Alpha5 Beta1 and its Ability to Regulate the Cell Survival Pathway 60/396,482
Application filed 2003 - 601-1-134PCT
European Patent filing 7/16/03 Application/Patent no. 03799816.8-2403-US0321954
2003 Development of microfluidics technology to map cell surface protein signatures for use in laboratory investigations, diagnosis, prognosis and treatment of disease. – in collaboration with Sarnoff Corporation, Princeton, NJ
2004 Molecular and Cellular Retardation Methods and the Encounter, or Interaction, Complex. – in collaboration with Sarnoff Corporation, Princeton, NJ

16. MAJOR TEACHING EXPERIENCE

1975-76 Teaching Assistant, Organic Chemistry Laboratory, Department of Chemistry, University of Pennsylvania, Philadelphia, PA.
1993-1998 Participated in Dept. Microbiology and Mol. Genetics Mol. Biology Journal Club

1993	Lectured in the New Jersey Medical School Immunology course
1994-1996	Supervised Clinical Oncology Fellows on the wards and in clinic
1994-1996	Conducted Clinical Oncology Journal Club
1994-present	Lectured to New Jersey Medical School Internal Medicine Residents
1994-present	Lectured annually in the New Jersey Medical School Introduction to Clinical Sciences course, Participated in physical diagnosis sessions
1994-present	Lectured annually in Medical Student Summer Cancer Biology Research Program
1995, 1997	Lectured in the UMDNJ-Graduate School of Biomedical Sciences Biology of Human Tumors Course,
1995-2001	Lectured annually in the New Jersey Graduate School Microbial Genetics II Course
2001	UNDNJ-NJMS Mini Med School - How Cancer is Treated
2001, 2003, 2005	Lectured in the UMDNJ-Graduate School of Biomedical Sciences Molecular and Immunopathologic Mechanisms of Cancer
2003	Lectured in Oncology Nurses training course, UMDNJ-University Hospital
2003	Lectured in UMDNJ-NJMS Medical Residents Conference, UMDNJ-UH
2004	Lectured in UMDNJ-NJMS Physical Medicine and Rehabilitation Residents Conference, Kessler Institute for Rehabilitation
2006	Lectured in UMDNJ-NJMS Medical Residents Conference, UMDNJ-UH
2006	Medical Student Transition Curriculum presentation on CBCs
2008	Lectured in UMDNJ-NJMS Medical Residents Conference, UMDNJ-UH
2008, 2009	Course Director, Principles of Clinical and Translational Research in Oncology, UMDNJ-GSBS GSND 5235Q
2009	Lectured in UMDNJ-NJMS Medical Residents Conference, UMDNJ-UH

MEMBER GRADUATE THESIS OR EXAMINATION COMMITTEES

Jennifer B. Jones (Department of Laboratory Medicine and Pathology, UMDNJ-Graduate School of Biomedical Sciences)

Jackie Washington (Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences)

Daniel Aviv (Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences)

Xuening Wang (Department of Laboratory Medicine and Pathology, UMDNJ-Graduate School of Biomedical Sciences)

Qing Mei Wang (Department of Laboratory Medicine and Pathology, UMDNJ-Graduate School of Biomedical Sciences)

James Nugent (Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences)

Achal Trivedi (Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences)

Roman Wernyj (Department of Biochemistry and Molecular Biology, UMDNJ-Graduate School of Biomedical Sciences)

Jennifer Czarneski (Department of Laboratory Medicine and Pathology, UMDNJ-Graduate School of Biomedical Sciences)

Sahba Kianifard (Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences)
Melanie K. Lenahan (Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences)
Kathy Piparo (Department of Biochemistry and Molecular Biology, UMDNJ-Graduate School of Biomedical Sciences)
Megan Fredericks (Department of Biochemistry and Molecular Biology, UMDNJ-Graduate School of Biomedical Sciences)
Wei Bu (Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences)
Anoop Kavirayani (Department of Microbiology and Molecular Genetics, UMDNJ-Graduate School of Biomedical Sciences)
Pedro L. Rodriguez (Biomedical Sciences Program, UMDNJ-Graduate School of Biomedical Sci.)
Shan Jiang (Department of Biochemistry and Molecular Biology, UMDNJ-Graduate School of Biomedical Sciences)
Zhaoyu Sun (Biomedical Sciences Program, UMDNJ-Graduate School of Biomedical Sci.)
Gwen Mahon (Biomedical Sciences Program, UMDNJ-Graduate School of Biomedical Sci.)
Edward Garay (Biomedical Sciences Program, UMDNJ-Graduate School of Biomedical Sci.)
Ethan Fitzpatrick (Biomedical Sciences Program, UMDNJ-Graduate School of Biomedical Sci.)
Ahmet Tonceroglu (Biomedical Sciences Program, UMDNJ-Graduate School of Biomedical Sci.)
Xiangwen Chen (Department of Laboratory Medicine and Pathology, UMDNJ-Graduate School of Biomedical Sciences)
Crystal DiCosmo (Department of Laboratory Medicine and Pathology, UMDNJ-Graduate School of Biomedical Sciences)

TRAINING SUMMER AND ROTATING STUDENTS

1994 Karen Finnigan
- won first prize in Summer Student Cancer Research Symposium
- won The Research Award for Scientific Excellence at the New Jersey State Commission on Cancer Research Annual Research Symposium, 1995

1994 Paul Maloof
1995 John Chung
1995 Daniel Fulop
1996 Christine Torigian
1996 Michelle A. Fanale
- first prize, Summer Student Cancer Research Symposium
- second prize, Annual NJMS Summer Student Res. Symp. (highest allowed)
  - first prize, First UMDNJ Statewide Med. Student Resch. Competition, 1997
  - Went on to Medical Oncology Fellowship at MD Anderson Cancer Center

1996 Annie Lin
1997 Mark Solomon
1997 Myrna S. Uytingco
- won second prize in Summer Student Cancer Research Symposium

1997 Joseph Golowa
1997 Renato Apolito

- won first prize in NJMS Summer Student Cancer Research Symposium

1999 Lydia Choi
- selected as 1 of 40 students nationally for oral presentation at The National Student Research Forum, University of Texas Medical Branch, Galveston, TX
- won The National Student Research Forum Oncologic Research Award,

2000 - won the Gallo Research Award for Scientific Excellence, 2000 Annual Retreat on Cancer Research in New Jersey, CINJ and the NJCCR

2004 - Went on to Cancer Research Fellowship at Sloan Kettering

1999 Elizabeth Scheff
- won first prize in NJMS Summer Student Cancer Research Symposium
- won first prize in NJMS Summer Student Research Symposium
- selected as 1 of 40 students nationally for oral presentation at The National Student Research Forum, University of Texas Medical Branch, Galveston, TX

2000 Ilan Seth Weinberg
Jeaudine Evadne Bontemps
Mateusz Opyrchal (MD/PhD rotation)
Jason Solomon

2001 Wei Bu (PhD rotation)

2001 Judith Barrios (PhD rotation)

2002 Michael Lindy - won Award for Scientific Excellence at the CINJ-New Jersey State Commission on Cancer Research Annual Retreat, 2002

2002 Ankoor Shah
- won travel award to National Meeting in NJMS Summer Student Cancer Research Symposium

2003 Vineetha Joseph
- won book award in NJMS Summer Student Cancer Research Symposium

2003 Michael Lindy -
- won travel award to National Meeting in NJMS Summer Student Cancer Research Symposium
- selected as 1 of 40 students nationally for oral presentation at The National Student Research Forum, Univ. of Texas Medical Branch, Galveston, TX

2004 Mark Solomon
- won book award in NJMS Summer Student Cancer Research Symposium

2004 Bryan Benn – MD/PhD student
- won book award in NJMS Summer Student Cancer Research Symposium

2005 Ethan Fitzpatrick (PhD rotation)

2005 Sylvia Vasquez

2006 Joanna Sesti

2006 Ahmet Tunceroglu (MD/PhD rotation)

2006 Aaron Rockoff (with Dr. Christakos, Biochemistry)

2007 Tara Tendler

TRAINING POST-DOCTORAL FELLOWS

1995-2000 Qin Wang, MD
- won The New Jersey Research Award for Scientific Excellence (Smith-Kline Beecham Oncology, 1997

- won New Jersey Cancer Commission Outstanding Breast Cancer Research Post-Doctoral Fellowship, 1997
- won Gallo Research Award for Scientific Excellence at the New Jersey State Commission on Cancer Research Annual Retreat, 1999, 2000

2001-2002 Petra Archibald, PhD

- won The Gallo Research Award for Scientific Excellence at the New Jersey State Commission on Cancer Research Annual Retreat, 2001
- won the 2001 American Association for Cancer Research Minority Scholars in Cancer Research Award
- won the 2001 American Association for Cancer Research-Inglenook Vineyards Scholar-in-Training Award

2001-2002 Rachna Chandra, PhD
2003 Monika Boots, PhD

TRAINING GRADUATE STUDENTS

2002-2009 Judith Barrios (PhD)
2007-2008 Christopher K. Hansen (MS)

TRAINING FACULTY

2004-2006 Mentor for ASCO Young Investigator Award to Eric Cohen, MD, Assistant Professor, Dept. of Surgery, UMDNJ-NJMS

PROFESSIONAL ACTIVITIES

1988 Speaker: ZWO/TNO/NIH Symposium on Factors and Vectors in Hemopoiesis, The Hague, The Netherlands. Title: Use of retrovirally-mediated gene transfer for gene therapy in ADA deficiency.

1992 Speaker: American Society of Clinical Oncology, San Diego, CA. Title: Retroviral gene transfer of the hbFGF gene in human stroma.

1992 Speaker: International Society of Hematology, Providence, RI. Title: Cycle-activation of high proliferative potential cells (HPPC) in mice administered high doses of cytosine arabinoside (Ara-C).

1994 Speaker: American Society of Clinical Oncology, Dallas, TX. Title: MCF7 human breast cancer cells are negatively regulated by overexpression of basic fibroblast growth factor (bFGF).

1994-2006 Speaker, approx. 2 times/year UMDNJ-University Hospital Tumor Conference

1995 Speaker: Fourth International Conference on Gene Therapy of Cancer, San Diego, Ca. Title: Overexpression of retrovirally transduced basic FGF in MCF-7 human breast cancer cells downregulates Bcl-2 and sensitizes cells to chemotherapy-induced apoptosis.

1996 Speaker: First Annual New Jersey Breast Cancer Research Symposium, Rider University, Lawrenceville, NJ. Title: Basic FGF causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G_1 events.

1997 Speaker: Second Annual New Jersey Breast Cancer Research Symposium, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ. Title: 1,25-Dihidroxyvitamin D_3 and all-*trans* retinoic acid sensitize breast cancer cells to the effects of chemotherapeutic agents.

1998 Speaker at Cancer Institute of New Jersey Protocol Advisory Committee meeting

1998 Plenary Session Speaker at The Annual Retreat on Cancer Research in New Jersey
1999 Session Speaker at The Annual Retreat on Cancer Research in New Jersey
1999 Plenary Session Speaker, The Third New Jersey Breast Cancer Research Symposium
1999 Speaker, ACS/Cancer Care/CINJ/NJCCR/NJHD/St. Barnabas Hosp. Conference on Critical Decisions in Cancer for the 21st Century, Iselin NJ,
2000 Plenary Session Speaker, The Department of Defense Breast Cancer Research Program Meeting, "Era of Hope". Atlanta, GA, June 2000
2001 Speaker at Cancer Institute of New Jersey Protocol Advisory Committee meeting
2001 Speaker at the New Jersey State Commission on Cancer Research Symposium, "Sharing Perspectives on Cancer Research: Cancer Researchers Reach Out", Rider University, Lawrenceville, NJ
2002 Session Chair, Transcriptional regulation and oncogenensis/molecular mechanisms of tumor growth. Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research.
2006 Session Chair and Speaker, 10th Anniversary of the New Jersey Breast Cancer Research Fund Symposium

Seminars Given:

1993 Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, NY
1993 Department of Microbiology and Molecular Genetics, UMDNJ-NJ Medical School
1994 Department of Medicine Research Seminar, UMDNJ-NJ Medical School
1994 Hematology/Oncology Grand Rounds, East Orange Veterans Administration Hospital
1995 Hematology/Oncology Grand Rounds, New York Medical College
1995 Department of Laboratory Medicine and Pathology, UMDNJ-NJ Medical School
1996 The Center for Laboratory Investigation, UMDNJ-NJ Medical School
1996 Department of Surgery Research Conference, UMDNJ-NJ Medical School
1996 Department of Surgery Grand Rounds, UMDNJ-New Jersey Medical School
1997 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium
1997 Department of Medicine Research Seminar, UMDNJ-NJ Medical School
1998 Hematology/Oncology Grand Rounds, East Orange Veterans Administration Hospital
1998 Keynote Address, UMDNJ-NJMS Summer Student Cancer Research Symposium
1998 Department of Obstetrics and Gynecology Grand Rounds, UMDNJ-NJ Med. School
1999 Department of Obstetrics and Gynecology Resident Conference, UMDNJ-NJMS
1999 Department of Medicine Grand Rounds, East Orange Veterans Administration Hosp.
2000 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium
2000 Department of Medicine Grand Rounds, UMDNJ-New Jersey Medical School
2000 Department of Microbiology and Molecular Genetics, UMDNJ-NJ Medical School
2001 Department of Obstetrics and Gynecology Resident Conference, UMDNJ-NJMS
2001 Department of Anatomy, Cell Biology & Injury Sciences Res. Seminar UMDNJ-NJMS
2001 Speaker at Cancer Institute of New Jersey SPORE project seminar series
2001 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium
2001 Division of Urology, Dept. of Surgery Grand Rounds, UMDNJ-NJ Med. School
2001 Department of Medicine Research Seminar, UMDNJ-New Jersey Medical School
2002 Division of Endocrinology, Dept. Medicine Research Seminar, UMDNJ-NJMS
2002 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium
2003 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium

2003 Speaker at Cancer Institute of New Jersey breast cancer seminar series
2003 Seminar speaker at Rider University Department of Biology
2004 Research seminar, UMDNJ-University Hospital Tumor Board
2004 Speaker, UMDNJ-NJMS MD/PhD Student Research Seminar
2004 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium
2004 Speaker Governor's School Students Cancer Biology Course
2005 Speaker, UMDNJ-NJMS Biomedical Sciences Program Research Seminar Series
2005 Seminar speaker at Rider University Department of Biology
2005 Speaker, Hematology/Oncology Research Conference, East Orange VA Hospital
2005 Speaker, Division of Endocrinology Research Conference, UMDNJ-NJMS
2006 Speaker, Research Conference, Department of Medicine, UMDNJ-NJMS
2006 Overview of Paradigms for Clinical Research, UMDNJ-University Hospital Cancer Center Grand Rounds
2006 Speaker, Division of Endocrinology Research Conference, UMDNJ-NJMS
2007 Speaker, UMDNJ-NJMS MD/PhD Student Research Seminar
2007 Seminar speaker, Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School
2007 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium
2007 Speaker, UMDNJ-NJMS Summer Student Cancer Research Seminar Series
2008 Speaker, UMDNJ-NJMS Mini Med School
2008 Speaker, Cancer Institute of New Jersey Breast Cancer Program Seminar Series
2008 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium
2008 Speaker, McNair Summer Student Scholars Program, Rider University, Lawrenceville, NJ
2008 Speaker, UMDNJ-NJMS Premed Honors Program
2009 Speaker, UMDNJ-NJMS Summer Student Cancer Research Symposium

Meeting Organizer:

1996 Co-chair: First New Jersey Breast Cancer Research Symposium
1999 Co-chair: Third New Jersey Breast Cancer Research Symposium

Manuscript reviewer:

Biochemical Pharmacology
Biochimica et Biophysica Acta
British Journal of Cancer
Cancer
Cancer Letters
Cancer Research
Clinical Cancer Research
Endocrinology
Experimental Cell Research
FEBS Letters
Journal of Biological Chemistry
Journal of Cellular Biochemistry
Journal of Cellular Physiology

Molecular Cancer Therapeutics
Molecular Pharmacology
Oncogene
Pharmacological Research

Grant reviewer

1994-2000	Foundation of UMDNJ
2000	Dutch Cancer Society (*ad hoc*)
2001	National Science Foundation (*ad hoc*)
2003	Foundation for Science and Technology, Portugal Ministry of Science
2004	Department of Defense Breast Cancer Research Program ENDO-2 Study Section EPI-Adhoc Study Section, Chair
2005	Susan G. Komen Breast Cancer Foundation Tumor Cell Biology I Study Section
2005	National Cancer Institute, NIH Cancer Epidemiology/Cancer Prevention Small Grants Study Section
2006	Susan G. Komen Breast Cancer Foundation Tumor Cell Biology V Study Section
2006	Department of Defense Breast Cancer Research Program Molecular Biology & Genetics Peer Review Panel III
2007	Susan G. Komen Breast Cancer Foundation Tumor Cell Biology I Study Section
2007	California Breast Cancer Research Program Tumor Progression Review Committee
2007	National Science Foundation (*ad hoc*)
2007	National Cancer Institute, Innovative Technologies for Molecular Analysis of Cancer (IMAT) review panel
2007	Department of Defense Breast Cancer Research Program Molecular Biology & Genetics Peer Review Panel III
2008	Susan G. Komen Breast Cancer Foundation Tumor Cell Biology I Study Section
2008	National Cancer Institute, Innovative Technologies for Molecular Analysis of Cancer (IMAT) review panel
2008	California Breast Cancer Research Program Tumor Progression Committee
2008	Israeli Science Foundation (*ad hoc*)
2008	Department of Defense Breast Cancer Research Program Molecular Biology & Genetics Peer Review Panel II
2009	Chair, DOD Breast Cancer Research Program Concept Grant Molecular Biology & Genetics Peer Review Panel I
2009	Department of Defense Breast Cancer Research Program Molecular Biology & Genetics Peer Review Panel II
2009	Foundation of UMDNJ Biomedical Research Support Program
2009	Department of Defense Breast Cancer Research Program Molecular Biology & Genetics Peer Review Panel II

17. PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES
Weekly Oncology clinic, UMDNJ- University Hospital
Service Attending two months a year in Oncology, UMDNJ-University Hospital

18. MAJOR ADMINISTRATIVE RESPONSIBILITIES
1993-present Director, Laboratory of Molecular Oncology
1996-1999 Interim Director, Division of Oncology, Department of Medicine, UMDNJ-New Jersey Medical School
1999-2001 Interim Director, Division of Oncology/Hematology, Department of Medicine, UMDNJ-New Jersey Medical School
1998-2001, 2006-present Chair, NJ Commission on Cancer Research Breast Cancer Advisory Group
1998-2001 Associate Director, Clinical Research, UMDNJ-NJMS Cancer Center
1998-2003 Associate Director (clinical), P.D./PhD Program, UMDNJ-Graduate School of Biomedical Sciences
2005-present Director, Clinical Research Office, UMDNJ-NJ Medical School/ University Hospital Cancer Center
2009-present Co-Medical Director, Center for Clinical and Translational Science, UMDNJ-NJ Medical School

19. PRIVATE PRACTICE None

BIBLIOGRAPHY
20. ARTICLES

1. Jaynes EN, Grant PG, Giangrande G, **Wieder R**, Cooperman BS. (1978) Photoinduced affinity labeling of the Escherichia coli ribosome puromycin site. Biochemistry 17: 561-569.

2. **Wieder R**, Wetmur JG. (1981) One hundred-fold acceleration of DNA renaturation rates in solution. Biopolymers 20: 1537-1547.

3. **Wieder R**, Wetmur JG. (1982) Factors affecting the kinetics of DNA reassociation in phenol-water emulsion at high DNA concentrations. Biopolymers 21: 665-677.

4. **Wieder R**. (1982) Techniques for accelerating DNA renaturation and their preliminary application to gene isolation methods. Thesis. The City University of New York.

5. Cornetta K, **Wieder R**, Anderson WF. (1989) Gene transfer into primates and prospects for gene therapy in humans. Progress in Nucleic Acids Research and Molecular Biology 36:311-322.

6. **Wieder R**, Cornetta K, Kessler SW, Anderson WF. (1991) Increased efficiency of retroviral-mediated gene transfer and expression in primate bone marrow progenitors following 5-FU-induced hematopoietic suppression and recovery. Blood 77: 448-455.

7. **Wieder R**. (1991) Cryopreserved primate bone marrow cells can be used for retroviral-

mediated gene transfer. Human Gene Therapy 2: 323-326.

8. **Wieder R**, Barak V, Ben-Ishay Z. (1995) High-efficiency retroviral gene transfer into murine high-proliferative-potential cells cycle-activated by cytosine arabinoside. Human Gene Therapy 6: 865-871.

9. Menzel T, Rahman Z, Calleja E, White K, Wilson EL, **Wieder R**, Gabrilove J. (1996) Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87: 1056-1063.
10. Fenig E. **Wieder R**, Paglin S, Wang H, Persaud R, Haimovitz-Friedman A, Fuks Z, Yahalom J. (1997) Basic fibroblast growth factor confers growth inhibition and Mitogen-activated Protein Kinase activation in human breast cancer cells. Clinical Cancer Research 3: 135-142.

11. Wang H, Rubin M, Fenig E, DeBlasio T, Mendelsohn J, Yahalom J and **Wieder R**. (1997) Basic FGF causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G_1 events. Cancer Research 57: 1750-1757.

12. **Wieder R**, Wang H, Shirke S, Wang Q, Menzel T, Feirt N, Jakubowski AA and Gabrilove JL. (1997) Low level expression of basic FGF upregulates Bcl-2 and delays apoptosis, but high intracellular levels are required to induce transformation in NIH 3T3 cells. Growth Factors 15:41-60.
13. **Wieder R**, Fenig E, Wang H, Wang Q, Paglin S, Menzel T, Gabrilove J, Fuks Z, Yahalom J. (1998) Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation. J. Cellular Physiology 177:411-425.

14. Wang Q, Maloof P, Wang H, Fenig E, Stein D, Nichols G, Denny TN, Yahalom J and **Wieder R**. (1998) Basic fibroblast growth factor (bFGF) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Experimental Cell Research 238:177-187.

15. Maloof P, Wang Q, Wang H, Stein D, Denny TN, Yahalom J, Fenig E and **Wieder R.** (1999) Overexpression of retrovirally transduced basic FGF in MCF-7 human breast cancer cells downregulates Bcl-2 and sensitizes cells to chemotherapy-induced apoptosis. Breast Cancer Research and Treatment 56:153-167.

16. Fenig E, Livnat T, Sharkon-Polak S, Wasserman L, Beery E, Lilling G, Yahalom J, **Wieder, R**, Nordenberg J. (1999) Basic fibroblast growth factor potentiates cisplatinum-induced cytotoxicity in MCF-7 human breast cancer cells. J. Cancer Res. Clin. Onc. 125:556-562.

17. Korah R, Sysounthone V, Golowa Y, and **Wieder R**. (2000) Basic fibroblast growth factor confers a more differentiated phenotype in MDA-MB-231 human breast cancer cells. Cancer Research 60:733-740.

18. Wang Q, Yang W, Uytingco MS, Christakos S and **Wieder R**. (2000) 1,25$(OH)_2$ vitamin D_3 and all-*trans* retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.

Cancer Research. 60:2040-2048.

19. Korah R, Sysounthone V, Scheff E, and **Wieder R**. (2000) Intracellular FGF-2 promotes differentiation in T47-D breast cancer cells. Biochem. Biophys. Res. Comm. 277:255-260.

20. Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R, and **Wieder R**. (2001) 1,25-dihydroxyvitamin D_3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res. Treat. 67:157-168.

21. Fenig E, Kanfi Y, Wang Q, Beery E, Livnat T, Wasserman L, Lilling G, Yahalom J, **Wieder R** Nordenberg J. (2001) Role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor. Breast Cancer Res. Treat. 70: 27-37.

22. **Wieder R**, Pavlick AC, Bryan M, Hameed M, Baredes S, Pliner L, Saunders T and Korah R. (2002) Phase I/II trial of Accutane as a potentiator of carboplatin and Taxol in squamous cell carcinomas. American J. Clinical Oncology 25: 447-450.

23. **Wieder R**, Novick SC, Hollis BW, Bryan M, Chanel SM, Owusu K, Camastra D, Saunders T, Pliner L, Harrison J, Bonate P, Williams T, Soignet S. (2003) Pharmacokinetics and Safety of ILX23-7553, a Non-calcemic-Vitamin D_3 Analogue, in a Phase I Study of Patients with Advanced Malignancies. Investig. New Drugs 21: 445-452.

24. Wang Q and **Wieder R.** (2004) All-*trans* retinoic acid potentiates Taxotere-induced cell death mediated by jun N-terminal kinase in breast cancer cells. Oncogene 23: 426-433.

25. Korah R, Choi L, Barrios J and **Wieder R**. (2004) Constitutive expression of FGF-2 abrogates focal adhesion signaling in MDA-MB-231 breast cancer cells. Breast Cancer Research and Treatment 88: 17-28 (Erratum – color photos (2005) 89: 319 – 322).

26. Korah R, Boots M, and **Wieder R**. (2004) Integrin $\alpha5\beta1$ promotes survival of growth-arrested breast cancer cells: an *in vitro* paradigm for breast cancer dormancy in bone marrow. Cancer Research 64: 4514-4522.

27. Najmi S, Korah R, Chandra R, Abdellatif M, **Wieder R**. (2005) Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clinical Cancer Research 11:2038-2046.

28. **Wieder R**. Insurgent micrometastases: sleeper cells and harboring the enemy. (2005) J. Surgical Oncology 89:207-210.

29. Fitzpatrick E, McBride S, Yavelow J, Najmi S, Zanzucchi P and **Wieder R**. Microfluidic techniques for single cell protein expression analysis. (2006) Clin. Chem. 52:1080-1088.

30. Korah R, Das K, Lindy ME, Hameed M and **Wieder R**. Co-ordinate loss of FGF-2 and laminin 5 expression during neoplastic progression of mammary duct epithelium. (2007)

Human Pathology 38:154-160.

31. Bryan M, De La Rosa N, Hill AM, Amadio WJ, **Wieder R**. (2008) Influence of prescription benefits on pain control in patients with cancer. Pain Medicine 9:1148–1157.

32. Dhawan P, **Wieder R**, Christakos S. (2009) CCAAT Enhancer Binding Protein Alpha is a Molecular Target of 1,25Dihydroxyvitamin D_3 in MCF-7 Breast Cancer Cells. J. Biol. Chem. 284:3086-3095.

33. Barrios, J and **Wieder R**. (2009) Dual FGF-2 and intergrin α5β1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy. Cancer Microenvironment (in press).

21. BOOKS, MONOGRAPHS AND CHAPTERS

1. **Wieder R**, Kessler SW, Wagemaker G, Anderson WF. (1988) Differential retroviral gene transfer into primate bone marrow precursors fractionated on an albumin gradient. In: Gale RP and Champlin R, eds., UCLA Symposia on Molecular and Cellular Biology, New Series, vol 91: Bone Marrow Transplantation: Current Controversies, Alan R. Liss, Inc, New York, pp 379-388.

2. **Wieder, R**. Selection of Methods for Measuring Proliferation, in Cell Growth, Differentiation and Senescence: A Practical Approach. G. Studzinski, ed. Oxford University Press, New York, NY, 1999, pp 1-32.

3. **Wieder, R**. TUNEL assay as a measure of chemotherapy-induced apoptosis. Methods in Molecular Medicine, vol. 111: Chemosensitivity : Vol. 2: In Vivo Models, Imaging, and Molecular Regulators. R.D Blumenthal, ed., Humana Press, Inc., Totowa, NJ, 2005, pp 43-54.

22. ABSTRACTS

1. **Wieder R**, Wetmur JG. (1981) Optimum methods for acceleration of DNA renaturation rates. Federation Proceedings 40: 1849.

2. Zwiebel JA, Kantoff PW, Eglitis MA, Kohn D, Muenchau D, McLachlin JR, Karson E, **Wieder R**, Yu S-F, Blaese MR, Gilboa E, Anderson WF. (1986) Gene transfer and expression using a family of retroviral vectors. Blood 68: 307a.

3. Cornetta K, Moen R, Gillio A, Culver K, **Wieder R**, Blaese RM, O'Reilly R, Anderson WF. (1988) Fate of murine helper virus in non-human primates. J Cellular Biochem, Supplement 12B.

4. **Wieder R**, Zwiebel JA, Wagemaker G, Anderson WF. (1988) Enhanced retroviral gene transfer into primate bone marrow progenitor cells enriched by discontinuous albumin

gradients. J Cellular Biochem, Supplement 12C, K221.

5. **Wieder R**, Cornetta K, Kessler S, Anderson WF. (1988) Kinetics of 5-FU-induced bone marrow suppression and recovery: effects on the efficiency of retroviral gene transfer in non-human primates. Blood 72: 105a.

6. **Wieder R**, Cornetta K, Kessler S, Anderson WF. (1989) Improved efficiency of retroviral-mediated gene transfer and expression in primate hematopoietic progenitors following 5-FU-induced bone marrow suppression and recovery. J Cellular Biochem, Suppl. 13C, H229.

7. **Wieder R**, Shirke S, Kehagias E, Gilboa E, Rifkin DB, Wilson EL, Jakubowski AA, Gabrilove JL. (1991) Constitutive expression of retrovirally transduced basic FGF in NIH 3T3 cells causes phenotypic transformation and modulates hematopoiesis. Blood 78: 301a.

8. **Wieder R**, Shirke S, Kehagias E, Jakubowski A, Wilson EL, Gabrilove JL. (1992) In vitro stimulation of myelopoiesis by constitutive expression of basic FGF in retrovirally transduced NIH 3T3 cells. J Cellular Biochemistry, Supplement 16C, M446.

9. **Wieder R**, Shirke S, Kehagias E, Jakubowski AA, Wilson EL, Gabrilove JL. (1992) NIH 3T3 cells transduced with basic FGF stimulate myelopoiesis in vitro. J Cellular Biochemistry, Suppl. 16F, V229.

10. **Wieder R**, Shirke S, Wilson EL, Gabrilove JL. (1992) Retroviral Gene transfer of the human basic fibroblast growth factor (hbFGF) gene in human stroma. Cancer Biology and Molecular Genetics, 11:105, #241. (selected for oral presentation) (Winner of ASCO Travel Award)

11. **Wieder R**, Barak V, Ben-Ishay Z. (1992) Cycle-activation of high proliferative potential cells (HPPC) in mice administered high doses of cytosine arabinoside (Ara-C). Exp. Hem. 20:733, #113.

12. **Wieder R**, Gabrilove JL, Wilson EL, Golde DW, Raines MB. (1992) Constitutive overexpression of human basic fibroblast growth factor (bFGF) in retrovirally transduced NIH 3T3 cells causes phenotypic transformation and constitutive tyrosine phosphorylation of a 42 kD protein which co-migrates with microtubule-associated protein 2 (MAP2) kinase. Blood 80:305a.

13. Fenig E, Yahalom Y, **Wieder R**, Fuks Z, Haimovitz-Friedman A. (1994) Basic fibroblast growth factor inhibits the growth of human breast cancer cells. Proc. American Assoc. Cancer Res. 35:35. (selected for oral presentation)

14. **Wieder R**, Fenig E, Fuks Z, Yahalom J. (1994) MCF7 human breast cancer cells are negatively regulated by overexpression of basic fibroblast growth factor (bFGF). Proc.Am.Soc.Clin.Onc. 13:62, #52. (selected for oral presentation)

15. Fenig E, **Wieder R**, Maxy R, Fuks Z, Yahalom J. (1994) Overexpression of basic fibroblast growth factor confers negative growth regulation and radiosensitization in human breast cancer cells. Int. J. Radiation Oncology. 30 (suppl. 1):173. (selected for oral

presentation)

16. Menzel T, Rahman Z, White K, **Wieder R**, Gabrilove J. (1994) Elevated intracellular levels of basic fibroblast growth factor correlate with stage of chronic lymphocytic leukemia and confer resistance to fludarabine. Blood 84: 525a. (selected for oral presentation)

17. **Wieder R**, Barak V, Ben-Ishay Z. (1994) High efficiency retroviral gene transfer into high proliferative potential cells (HPPC) of mice treated with high doses of cytosine arabinoside (Ara-C). Blood 84: 356a.
18. **Wieder R**, Fenig E, Wang H, Paglin S, Fuks Z, Yahalom J. (1995) Nuclear and cytoplasmic moieties of basic fibroblast growth factor (bFGF) have alternate effects in MCF-7 human breast cancer cells. Proc. Amer. Assoc. Cancer Res. 36:48 #286.

19. Yahalom J, Fenig E, Rubin M, Menzel T, DeBlasio T, Fuks Z, **Wieder R**. (1995) The role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor. Proc. Amer. Assoc. Cancer Res. 36:46 #274.

20. Finnigan KJ, Fenig E, Wang H, Maloof P, Yahalom J, **Wieder R**. (1995) Growth inhibition of mammary epithelial cell lines by exogenous bFGF is affected by their intrinsic bFGF content. Proc.Am.Soc.Clin.Onc. 14:133, #230

21. Finnigan KJ, Fenig E, Wang H, Maloof P, Yahalom J, **Wieder R**. (1995) Intracellular content of bFGF in mammary epithelial cell lines modulates their response to exogenous bFGF. NJ Commission on Cancer Research Annual Workshop. (Received Award for Scientific Excellence)

22. Maloof P, Wang H, Stein D, Fenig E, Nichols G, Denny T, Yahalom, **Wieder R**. (1995) Overexpression of retrovirally transduced basic FGF in MCF-7 human breast cancer cells downregulates Bcl-2 and sensitizes cells to chemotherapy-induced apoptosis. Cancer Gene Therapy 2:337, P-105 (selected for oral presentation).

23. Maloof P, Wang H, Wang Q, Fenig E, Stein D, Nichols G, Denny T, Yahalom J and **Wieder R**. Basic fibroblast growth factor decreases Bcl-2 levels and sensitizes MCF-7 breast cancer cells to chemotherapy-induced apoptosis. Program Proceedings of American Society of Clinical Oncology, 1996, p114, #120.

24. **Wieder R**, Maloof P, Wang H, Fenig E, Yahalom. (1996) Basic fibroblast growth factor (bFGF) decreases Bcl-2 levels and sensitizes MCF-7 cells to etoposide- and 5-fluorouracil-induced apoptosis. Keystone Symposia on Breast and Prostate Cancer: Basic Mechanisms, p39, #B4-328.
25. Wang Q, Maloof P, Wang H, Stein D, Denny T and **Wieder R**. Basic fibroblast growth factor promotes chemotherapy-induced apoptosis in MCF-7 breast cancer cells and causes decreased Bcl-2 levels. (1996) Annual Retreat on Cancer Research in New Jersey, The Cancer Institute of NJ and the NJ State Commission on Cancer Research. p73, #101.

26. Nugent J, Wang H, **Wieder R** and Small M. Staurosporine induces G_1 arrest, decreased cdk4 levels and underphosphorylation of Rb in nontransformed but not Myc-transformed Rat-

1 fibroblasts. (1996) Annual Retreat on Cancer Research in New Jersey, The Cancer Institute of NJ and the NJ State Commission on Cancer Research. p60, #74.

27. Wang Q, Maloof P, Wang H, Stein D, Denny T and **Wieder R**. Basic FGF has opposite effects on survival in NIH 3T3 cells and MCF-7 human breast cancer cells. First Annual New Jersey Breast Cancer Research Symposium, October, 1996.

28. Wang H, Rubin M, Fenig E, DeBlasio A, Mendelsohn J, Yahalom J and **Wieder R**. Basic FGF causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G_1 events. First Annual New Jersey Breast Cancer Research Symposium, October, 1996 (selected for oral presentation).

29. **Wieder R**, Wang Q, Maloof P, Wang H, Stein D and Denny T. Basic FGF is a survival factor in NHI 3T3 cells but promotes cell death in MCF-7 human breast cancer cells. Keystone Symposia on Apoptosis and Programmed Cell Death, Tamarron, CO, 2/18/97 p50, #284.

30. **Wieder R**, Wang H, Rubin M, Fenig E, DeBlasio A and Yahalom J. Basic FGF inhibits MCF-7 human breast cancer cell proliferation but induces both mitogenic and inhibitory G_1 events. Keystone Symposia on Signal Transduction, Keystone, CO, 3/31/97 p67, #438.

31. **Wieder R**, Wang H, Rubin M, Fenig E, DeBlasio A and Yahalom J. Cell cycle inhibition in G_1 is the dominant effect of simultaneous mitogenic and inhibitory events induced by basic FGF in MCF-7 breast cancer cells. Program Proc. American Soc. of Clinical Onc., 1997, p549a, #1979.

32. Wang Q, Lee D, Wang H, Christakos S and **Wieder R**. Chemosensitization of breast cancer cells by 1,25-dihydroxyvitamin D_3 and all-*trans* retinoic acid. (1997) Annual Retreat on Cancer Research in New Jersey, The Cancer Inst. of NJ and the NJ State Comm. Cancer Research #109.

33. Wang H, Fenig E, Finnigan K, Lee D, Paglin S, Fuks Z, Yahalom J and **Wieder R**. Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation. (1997) Annual Retreat on Cancer Research in New Jersey, The CINJ and the NJ State Commission on Cancer Research #90.

34. Wang Q, Maloof P, Wang H, Stein D, Denny T and **Wieder R**. Basic fibroblast growth factor promotes apoptosis in breast cancer. Second Annual New Jersey Breast Cancer Research Symposium, October, 1997.
35. Lee D, Fanale M, Finnigan K, Wang Q and **Wieder R**. Selective growth inhibition and MAP kinase activation by basic fibroblast growth factor in breast cancer cell lines. Second Annual New Jersey Breast Cancer Research Symposium, October, 1997.

36. Wang Q, Uytingco M, Apolito R, Lee D, Christakos S and **Wieder R**. 1,25-Dihidroxyvitamin D_3 and all-*trans* retinoic acid sensitize breast cancer cells to the effects of chemotherapeutic agents. Second Annual New Jersey Breast Cancer Resch. Symp., October, 1997 (selected for oral pres.).

37. **Wieder R**, Lee D, Wang Q, Uytingco M and Christakos S. Differentiation of breast cancer cells by all-*trans* retinoic acid and 1,25-dihydroxyvitamin D_3. Biomedicine '98, Washington, DC, May, 1998, #139.

38. Fanale M, Korah R, Finnigan K, Lee D, Wang Q and **Wieder R**. Basic fibroblast growth factor inhibits proliferation in breast cancer cells expressing FGF receptor 4. Program Proceedings of American Society of Clinical Oncology, 1998, #532.

39. **Wieder R**, Wang Q, Uytingco M, Apolito R, Lee D, Yang W and Christakos S. 1,25-dihydroxyvitamin D_3 and all-*trans* retinoic acid promote apoptosis and sensitize breast cancer cells to the effects of chemotherapeutic agents. Program Proc. American Society of Clinical Oncology, 1998, #413.

40. Wang Q, Lee D, Christakos S and **Wieder R**. Differentiation of breast cancer cells by 1,25-dihydroxyvitamin D_3 and all-*trans* retinoic acid. (1998) Annual Retreat on Cancer Research in New Jersey, The Cancer Institute of NJ and the NJ State Commission on Cancer Research (Selected for Plenary Session oral presentation PII).

41. Wang Q, Maloof P, Fenig E, Stein D, Denny T, Yahalom J and **Wieder R**. Paradoxic promotion of programmed cell death in breast cancer cells by basic fibroblast growth factor. (1998) Annual Retreat on Cancer Research in New Jersey, The Cancer Institute of NJ and the NJ State Comm. on Cancer Research, #49.

42. Wang Q, Maloof P, Fenig E, Stein D, Denny T, Yahalom J and **Wieder R**. Basic fibroblast growth factor promotes programmed cell death in breast cancer cells. (1998) Gordon Research Conference on Cancer (selected for oral presentation).

43. Korah R, Golowa Y, Sysounthone V, **Wieder R**. Expression of basic fibroblast growth factor (bFGF) induces a less malignant phenotype in human breast cancer cells. Program Proceedings of the American Association for Cancer Research, 1999, #2179, p. 329.

44. **Wieder R**, Sysounthone V and Korah R. Basic fibroblast growth factor promotes a less malignant phenotype, microtubule dissociation and focal adhesion kinase dephsophorylation in breast cancer cells. Program Proc. of American Society of Clinical Oncology, 1999, p617a, #2385.

45. Pavlick A, Korah R, Bryan M, Hameed M, Baredes S, Saunders T, Mueller M and **Wieder R**. Phase I/II trial of 13-*cis*-retinoic acid (Accutane), Paclitaxel (Taxol) and Carboplatin in recurrent or metastatic squamous cell carcinoma. Program Proceedings of American Society of Clinical Oncology, 1999, p223a, #858.

46. Wang Q. and **Wieder R**. All-*trans* retinoic acid potentiates apoptotic signaling by Taxol in breast cancer cells. (1999) Annual Retreat on Cancer Research in New Jersey, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, C2 (oral presentation)

47. Korah R, Sysounthone V and **Wieder R**. Basic FGF induces aberrant focal adhesion

signaling in breast cancer cells. (1999) Annual Retreat on Cancer Research in New Jersey, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, #49.

48. Sysounthone V, Lin A, **Wieder R** and Korah R. Promotion of a less malignant phenotype by basic fibroblast growth factor expression in breast cancer cells. (1999) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, #50.

49. Choi L, Sysounthone V, Korah R and **Wieder R**. FGF-2 modulates adhesion properties of breast cancer cells to induce a less malignant phenotype. (1999) Third New Jersey Breast Cancer Research Symposium.

50. Scheff E, Sysounthone V, **Wieder R** and Korah R. Intracellular FGF-2 inhibits breast cancer cell motility. (1999) Third New Jersey Breast Cancer Research Symposium.

51. Wang Q, Slimowitz R and **Wieder R**. Potentiation of Taxol-mediated apoptosis by all-*trans* retinoic acid (ATRA) in MCF-7 cells is associated with phosphorylation of JNK and AKt. (1999) Third New Jersey Breast Cancer Research Symposium (plenary presentation).

52. Zhu AZ, Fleischer M, Bush A, Childs B, Pearse R, **Wieder R** and Michaeli J. Elevated serum concentrations of fibroblast growth factor (FGF) in patients with multiple myeloma (MM). (1999) Blood 94 No. 10 (suppl. 1) p. 539a, #2409.

53. **Wieder R**, Choi L, Sysounthone V and Korah R. FGF-2 expression inhibits migratory response of breast cancer cells. Program Proceedings of the American Association for Cancer Research, 2000, p. 637, #4049 (selected for dicussion session).

54. Choi L, Sysounthone V, Korah R and **Wieder R**. Abrogation of migratory response by FGF-2 in breast cancer. (2000) The National Student Research Forum, The University of Texas Medical Branch, Galveston, TX. (selected for oral presentation, won Oncologic Research Award).

55. Scheff E, Sysounthone V, **Wieder R**, Korah R. FGF-2 inhibits cancer cell motility by modulating â1 integrins. (2000) The National Student Research Forum, The University of Texas Medical Branch, Galveston, TX. (selected for oral presentation).

56. Choi L, Korah R, **Wieder R**. Aberrant integrin signaling induced by FGF-2 alters adhesion properties of breast cancer cells. (2000) Annual Retreat on Cancer Research in NJ, The Cancer Inst. of NJ and NJ Comm. on Cancer Res., p15, Plenary Presentation II.
57. Scheff E, **Wieder R**, Korah R. Intracellular FGF-2 inhibits motility and promotes branching morphogenesis in breast cancer cells. (2000) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p.71, #87 .

58. Wang Q and **Wieder R**. Potentiation of paclitaxel-mediated apoptosis by all-*trans* retinoic acid (ATRA) in MCF-7 cells is associated with phosphorylation of JNK and Bcl-2. (2000) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 50, #46.

59. Korah R, Scheff E, Sysounthone V and **Wieder R**. Expression of intracellular FGF-2 in T-47D breast cancer cells inhibits motility and invasive potential. Program Proceedings of American Society of Clinical Oncology, 2000, p. 660a, #2604.

60. **Wieder R**, Pavlick A, Bryan M, Pliner L, Hameed M, Baredes S, Saunders T and Korah R. Final report on a phase I/II trial of 13-*cis*-retinoic acid (Accutane), Paclitaxel (Taxol) and Carboplatin in recurrent or metastatic squamous cell carcinoma. Program Proceedings of American Society of Clinical Oncology, 2000, p. 216a, #844.

61. Scheff E, Choi L, Sysounthone V, Korah R and **Wieder R**. Anti-motility signaling by intracellular FGF-2. The Department of Defense Breast Cancer Research Program Meeting, "Era of Hope". Atlanta, GA, June 2000, p. 454 (selected for platform presentation)

62. Bush A, **Wieder R**, and Michaeli J. The role of FGF signaling in the control of myeloma B-cell growth. (2000) Blood 96, No. 11 p. 754a, #3262.

63. **Wieder R**, Solomon J, Kallemuchikkal U, and Korah R. Intracellular FGF-2 blocks receptor-mediated breast cancer cell motility. Keystone Symposia on Cell Migration and Invasion, Tahoe City, CA, March, 2001, #121.

64. Q. Wang, and **R. Wieder**. Potentiation of Taxotere-induced cytotoxicity by all-*trans* retinoic acid and 1,25-dihydroxyvitamin D_3 in breast and prostate cancer cells. Program Proceedings of the American Association for Cancer Research 2001, v. 42, p 857, #4598.

65. P. Archibald, U. Kallemuchikkal, R. Korah and **R. Wieder**. FGF-2 blocks EGF-stimulated motility of breast cancer cells (2001) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Comm. on Cancer Res., p. 15, #A3 (focus presentation).

66. Q. Wang, RAS Chandraratna and **R, Wieder**. All-*trans* retinoic acid potentiates taxotere cytotoxicity while receptor agonist subtypes have cell-specific effects in breast cancer (2001) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 42, #011.

67. **R. Wieder**. J. Solomon, U. Kallemuchikkal, and R. Korah. Abrogation of receptor-mediated motility signaling by intracellular FGF-2 in breast cancer cells. (2001) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 76, #072.

68. M. Lindy, U. Kallemuchikkal, R. Korah, and **R. Wieder**. Beta-1 integrins modulate breast cancer cell motility. (2001) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 90, #096.

69. SC Novick, S Soignet, S Chanel, T Saunders, D Camastra, T Williams, and **R Wieder**. Phase I study of the vitamin D_3 analogue ILX23-7553 in patients with advanced malignancies. Program Proceedings of American Society of Clinical Oncology, 2001, v. 20., p. 119a, #472.

70. Wang Q, Chandraratna RAS and **Wieder R**. All-*trans* retinoic acid potentiates the killing effects of Taxotere in breast cancer cells. Gordon Research Conference on Chemotherapy of Experimental Clinical Cancer (2001).

71. Wang Q, and **Wieder R**. Roles of JNK activation and Bcl-2 phosphorylation in the potentiation effect of all-*trans* retinoic acid (ATRA) on paclitaxel-induced cell death in MCF-7 cells. Gordon Research Conference on Molecular Cell Biology (2001).

72. Archibald PA, Lindy M, Korah R and **Wieder R**. FGF-2 abrogates EGF-mediated motility of breast cancer cells. 2001 AACR-NCI-EORTC International Conference Miami Beach, FLA. #607, p 123, 2001.

73. Wang Q, Chandraratna R and **Wieder R**. Retinoic acid analogues sensitize breast cancer cells to the cytotoxic effects of Taxotere. 2001 AACR-NCI-EORTC International Conference, Miami Beach, FLA. #784, p 159, 2001.

74. Archibald PA, Lindy M, Korah R, and **Wieder R**. FGF-2 abrogates EGF-mediated motility of breast cancer cells and stabilizes SHP-2-Fak assembly. Keystone Symposia on Biological Response to the Extracellular Matrix, Banff Centre, Alberta, Canada, February, 2002, #107.

75. Archibald PA, Korah R, and **Wieder R**. FGF-2 stabilizes SHP-2-Fak interactions to block breast cancer cell motility. Program Proceedings of the American Association for Cancer Research 2002, v. 43, p 673, # 3340. (selected for poster discussion)

76. Korah RM, Hameed M, Archibald PA, and **Wieder R**. Laminin-5 inhibits differentiation of breast epithelial cells. Program Proceedings of the American Association for Cancer Research 2002, v. 43, p 5, # 22.

77. Chandra R, Korah R, and **Wieder R**. Effects of low dose Taxotere (docetaxel) on breast cancer cell cycle and cell death. (2002) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 62, #2.

78. Wang Q, Slimowitz R, and **Wieder R**. Effects and timing of Jun N-terminal kinase (JNK) activation in the potentiation of taxotere-induced cytotoxicity by all-*trans* retinoic acid (ATRA) in breast cancer cells. (2002) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 69, #17.

79. Archibald P, Lindy M, Korah R, and **Wieder R** FGF-2 promotes SHP-2-F-actin colocalization and blocks breast cancer cell motility. (2002) Annual Retreat on Cancer Res. in NJ, The Cancer Institute of NJ and the NJ State Comm. on Cancer Research, p. 79, #36.

80. Lindy ME, **Wieder R**, and Korah R. Laminin-5 inhibits dissemination of breast cancer cells. (2002) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p.83, #44. (won Award for Scientific Excellence)

81. Boots M, Korah R, and **Wieder R**. Fibronectin receptors promote survival of growth-arrested breast cancer cells on stromal proteins: a paradigm for breast cancer dormancy in

bone marrow. (2002) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 95, #68.

82. **Wieder R**, Novick SC, Hollis B, Bryan M, Chanel S, Owusu K, Camastra D, Saunders T, Pliner L, Harrison J, Bonate P, Williams T, Soignet S. Pharmakokinetics and Safety Profile of ILX23-7553, a Noncalcemic-Vitamin D_3 Analogue, in a Phase I Study of Patients with Advanced Malignancies. Program Proceedings of American Society of Clinical Oncology, 2002, v. 21., p. 77b, # 2119.

83. Wang Q, Slimowitz R, **Wieder R**. Role of Jun N-terminal Kinase (JNK) in the potentiation of Taxotere-induced cytotoxicity by all trans-retinoic acid (ATRA) in breast cancer cells. Program Proc. American Society of Clin. Onc., 2002, v. 21., p. 434a, # 1735.

84. Wang Q, **Wieder R**. Sustained Jun N-terminal Kinase (JNK) activation and potentiation of Taxotere-induced cell death by all *trans*-retinoic acid (ATRA) in breast cancer cells. Gordon Conference on Chemotherapy of Exp./Clinical Cancer (2002).

85. **Wieder R**, Boots M, and Korah R. FGF-2 induces breast cancer cell survival on fibronectin: a paradigm for breast cancer dormancy. The Department of Defense Breast Cancer Research Program Meeting, "Era of Hope". Orlando, FL, September 2002, # 25-23.

86. **R. Wieder** and Q. Wang. Role of Jun N-terminal Kinase (JNK) in potentiation of low dose Taxotere-induced cytotoxicity by all *trans*-retinoic acid (ATRA) in breast cancer cells. European Society of Clinical Oncology Annual Meeting, (2002) Annals of Oncology v. 13 Suppl. 5, p. 10, #35PD. (Selected for poster discussion).

87. R. Chandra, M. Boots, R. Korah, and **R. Wieder**. Flavopiridol inhibits FGF-2-induced phospho-Akt and inhibits clonogenic potential. ASCO Molecular Therapeutics Symposium (November, 2002) #85.

88. R. Korah, M. Boots, Q. Wang, **R. Wieder**. Flavopiridol inhibits Akt-signaling and blocks survival of dormant breast cancer cells. Proceedings of the American Association for Cancer Research 2003, v. 44, 2nd ed., p. 409, #2065.

89. **R. Wieder**, E. Fitzpatrick, J. Yavelow and S. McBride. A microfluidic system for single cell analysis of metastatic breast cancer cells. Proceedings of the American Association for Cancer Research 2003, v. 44, 2nd ed., p. 487, #2480.

90. A. Shah, R. Korah and **R. Wieder**. FGF-2 supresses EGF-mediated T-47D breast cancer cell motility. Proceedings of the American Association for Cancer Research 2003, v. 44, 2nd ed., p. 869, #4384.

91. **R. Wieder**, M. Boots, and R. Korah A model for metastatic breast cancer dormancy through fibronectin-mediated survival signaling. Program Proceedings of American Society of Clinical Oncology, 2003, v. 22. p. 23, # 89. (Selected for poster discussion).

92. **Robert Wieder**, Monika Boots, and Reju Korah. Integrin $\alpha 5\beta 1$ promotes survival of

growth-arrested breast cancer cells: an *in vitro* paradigm for breast cancer dormancy in bone marrow. (2003) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 33, #E2 (Selected for oral presentation}.

93. Saltanat Najmi, Vineetha Joseph, Monika Boots, Reju Korah and Robert Wieder Flavopiridol blocks integrin-mediated survival singnaling in dormant breast cancer cells. (2003) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 69, #P62 .

94. Ethan Fitzpatrick, Jonathan Yavelow, Sterling McBride and **Robert Wieder.** Development of a microfluidic system for single cell analysis of breast cancer cells (2003) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 96, # P61.

95. Ankoor Shah, Reju Korah and **Robert Wieder.** FGF-2 inhibits motility response to EGF in T-47D breast cancer cells. (2003) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 68, # P59.

96. Qin Wang and **Robert Wieder.** All-*trans* retinoic acid potentiates Taxotere-induced cell death mediated by jun N-terminal kinase in breast cancer cells. (2003) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, p. 67, #P58.

97. Fenig E, Kanfi Y, Wang Q, Beery E, Livnat T, Wasserman L, Lilling G, Yahalom J, **Wieder R**, Nordenberg J. (2003) Role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor. 8th World Congress on Advances in Oncology and 6th International Symposium on Molecular Medicine, Crete, Grece, 2003. Int. J. Mol. Med 12: (Suppl. 1) #367.

98. Mike Lindy, Reju Korah, Monika Boots, and **Robert Wieder**. Role of RhoA in survival of dormant breast cancer cells by basic fibroblast growth factor. Proceedings of the American Association for Cancer Research 2004, v. 45, #2435 p. 563 (oral presentation).

99. Ethan Fitzpatrick, Jonathan Yavelow, **Robert Wieder**, Peter Zanzucchi, Sterling McBride. Flow retardation of MCF-7 cells by immobilized ligands to cell surface receptors. Proceedings of the American Association for Cancer Research 2004, v. 45, # 2745 p. 633.

100. Michael E. Lindy, Reju Korah, Monika Boots, and **Robert Wieder**. Survival of dormant breast cancer cells depends on PI3 kinase and Rho signaling. (2004) The National Student Research Forum, The University of Texas Medical Branch, Galveston, TX. (selected for oral presentation).

101. Joseph, V, **Wieder, R.** All trans-retinoic acid modulates survival signaling in dormant breast cancer cells. Program Proceedings of American Society of Clinical Oncology, 2004, v. 23. # 422.

102. Korah R, Lindy M, Boots M, B. Benn and **Wieder R.** Interactions with the bone marrow microenvironment contribute to survival of breast cancer cells in a dormancy paradigm. Keystone Symposia on Microenvironment in tumor induction, Banff Centre, Alberta, Canada, February, 2005, p. 74, #333.

103. **Robert Wieder**, Saltanat Najmi, Rachna Chandra, Maha Abdellatif, Reju Korah. Flavopiridol disrupts adhesion and survival signaling in taxane-resistant dormant breast cancer cells. Proceedings of the American Association for Cancer Research 2005, v. 46, #5927, p.1394.

104. S Najmi, R Korah, M Abdellatif, **R Wieder**. Use of flavopiridol to disrupt adhesion and survival in dormant breast cancer cells. (2005) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, #116.

105. **R. Wieder**, M. Lindy, M. Boots, R. Korah . Survival signaling in dormant breast cancer cells. The Department of Defense Breast Cancer Research Program Meeting, "Era of Hope", June 2005, Philadelphia, p. 416, #P59-22.

106. Amadio WJ, Wang Q, Yavelow J, **Wieder R**. Cluster analysis of gene expression profiles of MCF-7 cells treated with all *trans*-retinoic acid (ATRA), paclitaxel or the two compounds in combination. Proceedings of the American Association for Cancer Research 2006, v. 47, #4931, p 1158.

107. J. Kertsman, E. Cohen, M. Abdellatif, **R. Wieder**. Modulation of integrin $\alpha 5$ in head and neck cancer cells by epidermal growth factor and its contribution to the malignant phenotype. Program Proceedings of American Society of Clinical Oncology, 2006, v. 25. # 15512

108. Barrios J and **Wieder R**. Regulation of Cytoskeletal Aberrations and Cellular Survival in Dormant Differentiated Breast Cancer Cells. (2006) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, #P48.

109. Amadio WJ, Wang Q, Yavelow J, and **Wieder R**. Modulation of distinct differentiation and survival signaling revealed by gene expression profiles of MCF-7 cells treated with all *trans*-retinoic acid (ATRA), paclitaxel or the combination. (2006) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, #P23.

110. Fitzpatrick E, McBride S, Yavelow J, Najmi S, Zanzucchi P, and **Wieder R**. Development of Microfluidic Techniques for Single Cell Protein Expression Analysis. (2006) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, Session D: Molecular Mechanisms of Tumor Growth II, Oral Presentation.

111. P. Dhawan, **R. Wieder** and S. Christakos. CCAAT Enhancer Binding Protein Alpha is a Molecular Target of 1,25Dihydroxyvitamin D_3 in Breast Cancer Cells. ASBMR 06 15-19 sept. 2006, Philadelphia.

112. Barrios J and **Wieder R**. FGF-2-induced breast cancer dormancy in an *in vitro* model is maintained through integrin α5β1 signaling. Proceedings of the American Association for Cancer Research 2007, v. 48, #2789, p.664-665.

113. Bryan M, De La Rosa N, Hill AM, Amadio WJ, **Wieder R**. Effects of prescription benefits on pain control in patients with cancer. (2007) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, #B3. (selected for oral presentation)

114. Barrios J and **Wieder R**. The differentiating effects of FGF-2 in an *in vitro* breast cancer dormancy model are mediated by signaling through integrin α5β1. (2007) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, #P47.

115. Tendler T, Cohen E, Kertsman J, **Wieder R**. Integrin signaling provides a survival advantage and relative chemoresistance to head and neck cancer cells. Proceedings of the American Association for Cancer Research 2008, v. 49, #1970, p 464.

116. **Robert Wieder** and Judith Barrios. Intergrin alpha 5 beta 1 causes stabilization of cortical actin fibers via focal adhesion signaling and downregulation of RhoA GTP in dormant breast cancer cells in an *in vitro* model. Department of Defense Breast Cancer Research Program (BCRP) Era of Hope 2008 Meeting, Balimore, MD, June 2008, P6544.

117. Judith Barrios and **Robert Wieder**. Dual FGFR and intergrin α5β1 signaling are necessary for GRAF-induced RhoA inactivation, cortical actin stabilization and focal complex formation in dormant breast cancer cells in an *in vitro* model. (2008) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, #

118. T. Tendler, E. Cohen, J. Kertsman, **R. Wieder**. The role of cell-matrix interactions in survival and relative chemoresistance of head and neck cancer cells. (2008) Annual Retreat on Cancer Research in NJ, The Cancer Institute of NJ and the NJ State Commission on Cancer Research, # P58.

23. REPORTS

1. Cornetta K, Fletcher JC, Karson E, Kohn DB, McLaghlin JR, Moen RC, **Wieder R**, Zwiebel JA (alphabetical) (1987) HUMAN GENE THERAPY PRECLINICAL DATA DOCUMENT, submitted to Human Gene Therapy Subcommittee, Recombinant DNA Advisory Committee, National Institutes of Health, by WF Anderson, RM Blaese, AW Nienhuis and RJ O'Reilly.

2. **Wieder R**, Wang H, Fenig E, Paglin S, Fuks Z and Yahalom J. Basic fibroblast growth factor induces both mitogenic and inhibitory signalling in MCF-7 cells. The Department of Defense Breast Cancer Research Program Meeting, "Era of Hope". Washington, DC, October 1997, vol.II: p. 393.

3. Choi L, Sysounthone V, Korah R and **Wieder R**. Abrogation of migratory response by FGF-2 in breast cancer. (2000) The National Student Research Forum, The University of Texas Medical Branch, Galveston, TX.

4. Scheff E, Sysounthone V, **Wieder R**, Korah R. FGF-2 inhibits cancer cell motility by modulating β1 integrins. (2000) The National Student Research Forum, The University of Texas Medical Branch, Galveston, TX.

5. **Wieder R.** Tackling dormant breast cancer metastases in the bone marrow. UMDNJ Research, Fall 2003:14-16.

6. Lindy M, Korah R, Boots M and **Wieder R**. Survival of dormant breast cancer cells depends on PI3K and Rho signaling, (2004) The National Student Research Forum, The University of Texas Medical Branch, Galveston, TX.

EXHIBIT B

Figure 1. Nonrad GEArray Q series gene chip microarray analysis of MCF-7 cells incubated with and without FGF-2 for 5 days on tissue culture dishes coated with fibronectin

A.



Figure 1. Nonrad GEArray Q series Human Extracellular Matrix and Adhesion Protein chip (Super Array, Bethesda, MD) microarray analysis of MCF-7 cells incubated for 5 days on tissue culture dishes coated with fibronectin 20 μg with and without the presence of FGF-2 10 ng/ml. Approximately one third as many cells remained in the FGF-2-treated population as in the control cells. Arrows point to integrin αV (solid line, spot 43) and β6 (dotted line, spot 50) mRNA's that are not expressed in the starting population and unchanged in the surviving population. Boxes are drawn around the control gene cDNAs on the two chips consisting of GAPDH, Cyclophyllin A, ribosomal L23 and β actin as positive controls and PUC18 plasmid DNA and blanks as negative controls.

Referece:

1. Mignatti P, Rifkin DB. (2000) Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. *Adv Cancer Res.* 78:103-57
2. Gumbiner BM (1996). Cell adhesion: the molecular basis of tissue architecture and morphogenesis. *Cell* 84: 345–357.
3. Ben-Ze'ev A, Geiger, B (1998) Differential molecular interactions of β-catenin and plakoglobin in adhesion, signaling and cancer. *Curr. Opin. Cell Biol.* 10: 629–639.
4. Ohene-Abuakwa Y, Pignatelli M (2000) Adhesion molecules in cancer biology. *Adv Exp Med Biol* 465: 115-126
5. Lo CW (1999) Genes, gene knockouts, and mutations in the analysis of gap junctions. *Dev. Genet.* 24: 1–4.
6. Burridge K., and M. Chrzanowska-Wodnicka. 1996. Focal adhesions, contractility, and signaling. *Ann. Rev. Cell Dev. Biol.* 12: 463–519.
7. Clezardin P (1998) Recent insights into the role of integrins in cancer metastasis. *Cell Mol Life sci* 54: 541-548
8. Werb, Z. (1997) ECM and cell surface proteolysis: regulating cellular ecology. *Cell* 91: 439–442.
9. Johansson N, et al (2000) Matrix metalloproteinases in tumor invasion. *Cell Mol Life Sci* 57: 5-15
10. Zieske JD.(2001) Extracellular matrix and wound healing *Curr Opin Ophthalmol* 12:237-41,
11. Sobel RA. (2001) The extracellular matrix in multiple sclerosis: an update. *Braz J Med Biol Res* 34:603-9
12. Schonherr E, Hausser HJ (2000) Extracellular matrix and cytokines: a functional unit. *Dev Immunol* 7:89-101
13. Raines EW. (2000) The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. *Int J Exp Pathol.* 81:173-82
14. Boluyt MO, Bing OH (2000) Matrix gene expression and decompensated heart failure: the aged SHR model. *Cardiovasc Res.* 46:239-49
15. Streuli C (1999) Extracellular matrix remodelling and cellular differentiation. *Curr Opin Cell Biol.* 11:634-40

Array Layout Table with Gene Symbol and Position Information

Human Adhesion & Extracellular Matrix Molecules GEArray Q series version 1

ADAMTS1 1	ADAMTS8 2	CASP8 3	CASP9 4	CAV1 5	CD44 6	CDH1 7	CEACAM5 8
CNTN1 9	COL18A1 10	COL1A1 11	COL4A2 12	CST3 13	CTNNA1 14	CTNNAL1 15	CTNNB1 16
CTNND1 17	CTNND2 18	CTSB 19	CTSD 20	CTSG 21	CTSL 22	DCC 23	ECM1 24
FGB 25	FN1 26	HPSE 27	ICAM1 28	ITGA1 29	ITGA10 30	ITGA11 31	ITGA2 32
ITGA2B 33	ITGA3 34	ITGA4 35	ITGA5 36	ITGA6 37	ITGA7 38	ITGA8 39	ITGA9 40
ITGAL 41	ITGAM 42	ITGAV 43	ITGAX 44	ITGB1 45	ITGB2 46	ITGB3 47	ITGB4 48
ITGB5 49	ITGB6 50	ITGB7 51	ITGB8 52	LAMB1 53	LAMC1 54	MGEA5 55	MICA 56
MMP1 57	MMP10 58	MMP11 59	MMP12 60	MMP13 61	MMP14 62	MMP15 63	MMP16 64
MMP17 65	MMP2 66	MMP20 67	MMP24 68	MMP26 69	MMP3 70	MMP7 71	MMP8 72
MMP9 73	NCAM1 74	NRCAM 75	PECAM1 76	PLAT 77	PLAU 78	PLAUR 79	SELE 80
SELL 81	SELP 82	SERPINB2 83	SERPINB5 84	SERPINE1 85	SPARC 86	SPP1 87	THBS1 88
THBS2 89	THBS3 90	TIMP1 91	TIMP2 92	TIMP3 93	TMPRSS4 94	VCAM1 95	VTN 96
PUC18 97	PUC18 98	PUC18 99	Blank 100	Blank 101	Blank 102	GAPD 103	GAPD 104
PPIA 105	PPIA 106	PPIA 107	PPIA 108	RPL13A 109	RPL13A 110	ACTB 111	ACTB 112

Position	UniGene	Genebank Acc#	Symbol	Description	Gene name
1	Hs.8239	AF060152	ADAMTS1	A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1	Meth 1
2	Hs.271605	NM_007037	ADAMTS8	Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 mo	Meth 2
3	Hs.19949	NM_001228	CASP8	caspase 8, apoptosis-related cysteine protease	caspase 8
4	Hs.100641	U60521	CASP9	caspase 9, apoptosis-related cysteine protease	caspase 9
5	Hs.323469	NM_001753	CAV1	Caveolin 1, caveolae protein, 22kD	caveolin 1
6	Hs.169610	M59040	CD44	CD44 antigen (homing function and Indian blood group system)	CD44
7	Hs.194657	Z13009	CDH1	Cadherin 1, type 1, E-cadherin (epithelial)	E-cadherin
8	Hs.220529	NM_004363	CEACAM5	Homo sapiens carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5),	CEA
9	Hs.143434	U07819	CNTN1	Contactin 1	contactin 1
10	Hs.78403	AF018081	COL18A1	Collagen, type XVIII, alpha 1	Endostatin
11	Hs.172928	NM_000088	COL1A1	Collagen, type I, alpha 1	COL1A1
12	Hs.75617	X06810	COL4A2	Collagen, type IV, alpha 2	COL4A2
13	Hs.135084	NM_000099	CST3	Homo sapiens cystatin C (amyloid angiopathy and cerebral hemorrhage) (CST3),	cystatin C
14	Hs.178452	NM_001903	CTNNA1	Catenin (cadherin-associated protein), alpha 1 (102kD)	catenin α1
15	Hs.58468	NM_003798	CTNNAL1	Catenin (cadherin-associated protein), alpha-like 1	catenin alpha-like 1
16	Hs.171271	NM_001904	CTNNB1	Catenin (cadherin-associated protein), beta 1 (88kD)	catenin β1
17	Hs.168011	AF062343	CTNND1	Catenin (cadherin-associated protein), delta 1	catenin δ1
18	Hs.80220	U96136	CTNND2	Catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein)	catenin δ2
19	Hs.249982	L16510	CTSB	Cathepsin B	Cathepsin B
20	Hs.79572	M11233	CTSD	Cathepsin D (lysosomal aspartyl protease)	cathepsin D
21	Hs.100784	NM_001911	CTSG	Homo sapiens cathepsin G (CTSG),	cathepsin G
22	Hs.78556	X12451	CTSL	Cathepsin L	cathepsin L
23	Hs.211567	NM_005215	DCC	Deleted in colorectal carcinoma	DCC
24	Hs.81071	NM_004425	ECM1	Homo sapiens extracellular matrix protein 1 (ECM1), transcript variant 1	ECM1
25	Hs.7645	J00129	FGB	fibrinogen, B beta polypeptide	fibrinogen β
26	Hs.287820	X02761	FN1	Fibronectin 1	fibronectin-1
27	Hs.44227	AF064467	HPSE	Homo sapiens heparanase mRNA	Heparanase
28	Hs.168383	NM_000201	ICAM1	intercellular adhesion molecule 1 (CD54), human rhinovirus receptor	ICAM-1
29	Hs.118774	X68742	ITGA1	Integrin, alpha 1	Integrin α1
30	Hs.158237	AF074015	ITGA10	Integrin, alpha 10	Integrin α10
31	Hs.256257	NM_012211	ITGA11	Integrin, alpha 11	Integrin α11
32	Hs.271986	X17033	ITGA2	Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)	Integrin α2/LFA1b
33	Hs.785	J02764	ITGA2B	Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41B)	Integrin alpha 2b
34	Hs.205829	M59911	ITGA3	Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)	Integrin α3
35	Hs.40034	L12002	ITGA4	Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)	Integrin α4 (VLA-4)
36	Hs.149609	X06256	ITGA5	Integrin, alpha 5 (fibronectin receptor, alpha polypeptide)	Integrin α5
37	Hs.227730	X53586	ITGA6	Integrin, alpha 6 subunit	Integrin α6
38	Hs.74369	NM_002206	ITGA7	Integrin, alpha 7	Integrin α7
39	Hs.91298	L36531	ITGA8	Integrin, alpha 8	Integrin α8
40	Hs.222	L24158	ITGA9	Integrin, alpha 9	Integrin α9
41	Hs.174103	NM_002209	ITGAL	Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide	Integrin αLLFA1a /(CD11A)
42	Hs.172631	J04145	ITGAM	Integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage an	Integrin αM
43	Hs.295726	NM_002210	ITGAV	Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)	Integrin αV
44	Hs.51077	X00993	ITGAX	Integrin, alpha X (antigen CD11C (p150), alpha polypeptide)	Integrin αX
45	Hs.287797	NM_002211	ITGB1	Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)	Integrin β1

Position	UniGene	Genebank Acc#	Symbol	Description	Gene name
				includes MDF2, MSK12)	
46	Hs.83968	Y00057	ITGB2	Integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1, macrophage antigen 1	Integrin β2
47	Hs.87149	J02703	ITGB3	Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)	Integrin β3/CD61
48	Hs.85266	X53587	ITGB4	Integrin, beta 4	Integrin β4
49	Hs.149846	J05633	ITGB5	Integrin, beta 5	Integrin β5
50	Hs.123125	NM_000888	ITGB6	Integrin, beta 6	Integrin β6
51	Hs.1741	M62880	ITGB7	Integrin, beta 7	Integrin β7
52	Hs.184008	NM_002214	ITGB8	Integrin, beta 8	Integrin β8
53	Hs.82124	M61916	LAMB1	Laminin B1 chain	laminin B1
54	Hs.214082	J03202	LAMC1	Laminin, gamma 1 (formerly LAMB2)	laminin G2
55	Hs.5734	NM_012215	MGEA5	Meningioma expressed antigen 5 (hyaluronidase)	Hyaluronidases
56	Hs.90508	NM_000247.1	MICA	Homo sapiens MICA gene, allele MICA*18	MUC-18
57	Hs.83109	X05231	MMP1	Matrix metalloproteinase 1 (interstitial collagenase)	collagenase-1
58	Hs.2255	NM_002425	MMP10	Matrix metalloproteinase 10 (stromelysin 2)	stromelysin 2
59	Hs.155324	X57766	MMP11	Human stromelysin-3	stromelysin-3
60	Hs.1695	L23808	MMP12	Matrix metalloproteinase 12 (macrophage elastase)	macrophage elastase
61	Hs.2936	X75308	MMP13	Matrix metalloproteinase 13 (collagenase 3)	collagenase-3
62	Hs.2399	D26512	MMP14	H.sapiens mRNA for membrane-type matrix metalloproteinase 1	MT1-MMP
63	Hs.80343	D86331	MMP15	Matrix metalloproteinase 15 (membrane-inserted)	MMP15
64	Hs.90800	D83648	MMP16	Matrix metalloproteinase 16 (membrane-inserted)	MMP16
65	Hs.159561	NM_016155	MMP17	Matrix metalloproteinase 17 (membrane-inserted)	MT-4-MMP
66	Hs.111301	J03210	MMP2	Matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 72kD type IV collagenase)	gelatinase A
67	Hs.128737	NM_004771	MMP20	Matrix metalloproteinase 20 (enamelysin)	enamelysin
68	Hs.3743	NM_006690	MMP24	Matrix metalloproteinase 24 (membrane-inserted)	MMP24
69	Hs.204732	AF216664	MMP26	Homo sapiens matrix metalloproteinase-26 (MMP26) mRNA	MMP26
70	Hs.83326	X05232	MMP3	Matrix metalloproteinase 3 (stromelysin 1, progelatinase)	stromelysin-1
71	Hs.2256	X07819	MMP7	Matrix metalloproteinase 7 (matrilysin, uterine)	matrilysin, uterine
72	Hs.73902	NM_002424	MMP8	Matrix metalloproteinase 8 (neutrophil collagenase)	neutrophil collagenase
73	Hs.151738	J05070	MMP9	Matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)	gelatinase B
74	Hs.107988	J03041	NCAM1	Neural cell adhesion molecule 1	NCAM
75	Hs.7912	NM_005010	NRCAM	neuronal cell adhesion molecule	NRCAM
76	Hs.78145	NM_000442	PECAM1	Homo sapiens platelet/endothelial cell adhesion molecule (CD31 antigen) (PECAM1),	PECAM-1
77	Hs.274404	NM_000930	PLAT	Homo sapiens plasminogen activator, tissue (PLAT),	tPA
78	Hs.77274	D00244	PLAU	Plasminogen activator, urokinase	uPA
79	Hs.179657	NM_002659	PLAUR	Human urokinase-type plasminogen activator receptor	uPAR
80	Hs.89546	X60040	SELE	Human endothelial leukocyte adhesion molecule 1 (ELAM1) mRNA	ELAM-1/E-selectin
81	Hs.82346	M25280	SELL	Selectin L (lymphocyte adhesion molecule 1)	L-Selectin
82	Hs.73800	NM_003005	SELP	selectin P (granule membrane protein 140kD, antigen CD62)	P-selectin
83	Hs.75716	J02885	SERPINB2	Human plasminogen activator inhibitor (PAI-2)	PAI-2
84	Hs.55279	NM_002639	SERPINB5	protease inhibitor 5 that has been shown to function as tumor suppressor in breast and prostate cancers	maspin
85	Hs.82085	M15006	SERPINE1	Plasminogen activator inhibitor, type I (PAI-1)	PAI-1
86	Hs.111779	NM_003969	SPARC	Homo sapiens secreted protein, acidic, cysteine-rich (osteonectin) (SPARC),	SPARC
87	Hs.313	M83248	SPP1	Homo sapiens secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) (SPP1),	osteopontin
88	Hs.87409	NM_003246	THBS1	Homo sapiens thrombospondin 1 (THBS1),	TSP-1
89	Hs.106033	L12350	THBS2	Human thrombospondin 2 (THBS2) mRNA	TSP-2
90	Hs.166875	L38969	THBS3	Homo sapiens thrombospondin 3 (THBS3) gene	TSP-3

Position	UniGene	Genebank Acc#	Symbol	Description	Gene name
91	Hs.5631	NM_003254	TIMP1	Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)	TIMP1
92	Hs.6441	NM_003255	TIMP2	Tissue inhibitor of metalloproteinase 2	TIMP2
93	Hs.245188	NM_000362	TIMP3	Tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory)	TIMP3
94	Hs.83325	NM_016425	TMPRSS4	Transmembrane protease, serine 4	TMPRSS4
95	Hs.100225	X53057	VCAM1	vascular cell adhesion molecule 1	VCAM1
96	Hs.2257	X03168	VTN	Vitronectin (serum spreading factor, somatomedin B, complement S-protein)	Vitronectin
97	N/A	L08752	PUC18	PUC18 Plasmid DNA	pUC18
98	N/A	L08752	PUC18	PUC18 Plasmid DNA	pUC18
99	N/A	L08752	PUC18	PUC18 Plasmid DNA	pUC18
100	Blank	Blank	Blank	Blank	0
101	Blank	Blank	Blank	Blank	0
102	Blank	Blank	Blank	Blank	0
103	Hs.169476	M33197	GAPD	Glyceraldehyde 3-phosphate dehydrogenase	GAPDH
104	Hs.169476	M33197	GAPD	Glyceraldehyde-3-phosphate dehydrogenase	GAPDH
105	Hs.182937	NM-021130	PPIA	Homo sapiens peptidylprolyl isomerase A (cyclophilin A) (PPIA)	cyclophilin A
106	Hs.182937	NM-021130	PPIA	Homo sapiens peptidylprolyl isomerase A (cyclophilin A) (PPIA)	cyclophilin A
107	Hs.182937	NM-021130	PPIA	Homo sapiens peptidylprolyl isomerase A (cyclophilin A) (PPIA)	cyclophilin A
108	Hs.182937	NM-021130	PPIA	Homo sapiens peptidylprolyl isomerase A (cyclophilin A) (PPIA)	cyclophilin A
109	Hs.119122	NM_012423	RPL13A	Ribosomal protein L13a(23 Kda highly basic protein)	RPL13A
110	Hs.119122	NM_012423	RPL13A	Ribosomal protein L13a(23 Kda highly basic protein)	RPL13A
111	Hs.288065	X00351	ACTB	Beta Actin	b-actin
112	Hs.288065	X00351	ACTB	Beta Actin	b-actin